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ABSTRACT

Melanomas are among the most common skin tumors in horses (second only to sarcoids),
with prevalence rates reaching as high as 80% in adult gray horses. Despite the wide
availability of measures of local control, there are currently no systemic therapies that can
effectively prevent spread, or treat metastatic or locally advanced/non-resectable
melanoma in horses. A form of gene immunotherapy based on a plasmid DNA construct
containing a xenogeneic form of the antigen tyrosinase have been developed and
optimized for targeting cancer in both humans and dogs; and have demonstrated
significant immunoreactivity and clinical benefit in the treatment of melanocytic tumors
in these species. This study describes how our group has performed all the necessary
steps to extend this therapy to a new species: The horse. This project has taken this idea
all the way from conceptualization to: (1) proof of target, by demonstrating tyrosinase
overexpression in equine melanomas and thus supporting its role as a valid tumor antigen
in this species; (2) to the identification of the best administration strategies for this
vaccine; (3) to the evaluation of the vaccine’s ability to induce a tyrosinase-specific
immune response in vaccinated horses, both healthy and melanoma-bearing.
This last step included the first (modified) phase I dose escalation study with this
immunotherapy in this species. To this objective antigen-specific humoral and cellular
immunoassays optimized to tyrosinase immunoreactivity. Tyrosinase xenogeneic
vaccination was able to induce a significant antigen-specific immune response, both
humoral and cellular, in most of the vaccinated patients. Dose appeared, however, not to
have a significant effect in this response. Toxicity data was also documented, and this
DNA vaccine appears to be safe and well tolerated in horses.
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Chapter 1 : Introduction
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Introduction

Melanomas have been recognized in horses for centuries and are among the most
common skin tumors in this species (3.8 and 15% of all skin tumors), second only to
sarcoids. [1-4] Furthermore, gray horses show a marked predisposition towards this
disease, reaching prevalence rates as high as 80%. [5-8] The overwhelming majority of
melanocytic tumors are benign at initial presentation; however, if left untreated up to 2/3
can progress to overt malignant behavior [4]. These tumors will not only eventually lead
to euthanasia, but will gradually affect the horses’ performance, resulting in a
considerable health and economic impact in the equine community. Despite the high
frequency of these tumors, there is currently no systemic treatment that can effectively
manage metastatic spread and hold on progression. Standard local treatment options can
be used to treat solitary early-stage lesions but do not address the underlying risk of
recurrent tumor formation or metastatic spread; effective novel therapies are thus greatly
needed.

Working hypothesis

The central

hypothesis of this project is

that antigen-specific gene

immunotherapy, using a Xenogenic DNA plasmid (pING-HuTyr) to target an immune
response against the melanoma protein tyrosinase, will prove to be both safe and able to
generate measureable immunologic responses in horses with melanocytic tumors.

2

Specific aims

1. To determine if the melanocyte differentiation antigen tyrosinase is preferentially
expressed or/and significantly overexpressed in equine dermal melanomas in
comparison to their normal skin counterpart. This is a necessary prerequisite to
determine if it can function as a target for the immunotherapeutic treatment of
melanomas in horses (Figure 1.1).
2. To compare two different needle-free injection devices and identify which will most
effectively deliver drugs into the muscle tissues of horses. Simultaneously we will
determine which one of the typical vaccination sites used in horses is the ideal
location for intramuscular drug delivery using this device (Figure 1.1).
3. To determine if a DNA plasmid encoding the gene for human tyrosinase (pINGHuTyr) is able to induce a measurable antigen-specific immune response in normal
equine patients receiving the plasmid via intramuscular delivery (Figure 1.1).
4. To document toxicity in normal horses treated with this DNA plasmid vaccine.
5. To determine if a DNA plasmid encoding the gene for human tyrosinase is able to
induce a measurable antigen-specific immune response in horses diagnosed with
melanomas and to document any toxicity following therapy in this same group.
6. A secondary aim in a subset of this group of horses is to determine the effect of
increasing the dose of DNA plasmid on immune response and toxicity

3
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Appendix of Tables and Figures

Figure 1.1. Simple funnel process chart graphing the three preliminary studies that were performed prior to
the clinical trial of this novel immunotherapeutic.

5

Chapter 2 : Literature Review
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1. Malignant Melanoma

Melanocytes are dendritic cells derived from neuroectodermal melanoblasts that
have migrated during embryogenesis to the epidermis, dermis, and other sites (e.g., eye,
hair, inner ear, meninges, bones, heart). Through a process called melanogenesis, these
cells produce the pigment melanin. The color of the melanin is dark and it absorbs all the
UV-B light and it blocks it from passing the skin layer into the hypodermis, and so
carrying out its purpose (and that of melanogenesis) of protecting it from the harmful
effects of solar UV-A and B radiation (DNA photodamage) [1]
Melanomas on the other hand are neoplastic lesions that arise from the
transformation of these once normal cells into their neoplastic variants in a multistep
process, with initiation as the first event, followed by promotion, progression, and finally
metastasis. Virtually nothing is known about initiation of most animal melanomas, but in
as many as 65% of cutaneous melanomas in humans is reported to occur secondary to
mutations generated by both UVA and UVB solar radiation (mainly by formation of
anomalous pyrimidine dimers). [2,3] Breed and familial clustering in domestic animals
suggest that genetic susceptibility may be critical to the initiation step. [4] In humans and
in most domestic animals (with the exception of gray horses) initiation within benign,
precursor lesions (e.g., melanocytic nevus) contributes to only a small percentage of
melanoma cases and most are believed to arise de novo [4,5]. The next step in
carcinogenesis requires promoting factors (e.g., chronic trauma, chemicals, burns) that
stimulate proliferation of the mutated cell, allowing for amplification of the cell
population, persistence of the mutation, and opportunities for additional mutations. [6]
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This genetically or environmentally initiated DNA instability facilitates
subsequent neoplastic transformation. Where the balance between the action of genes in
charge of suppressing cell proliferation and the ones in charge of promoting it is lost, and
eventually superseded by dysregulated growth factors or growth factor receptors (such as
bFGF, PDGFa and MSH) and inhibitors of apoptosis [7-9]. Loss of function mutations
involving several tumor suppressor genes have been implicated in the pathogenesis of
melanomas, among them INK4, Waf-1, bcl-2 [8,10] and p53; although the significance of
the latter remains inconclusive in human melanomas and especially in animal melanomas
(where even overexpression of normal p53 has been detected in equine tumors). [11] On
the opposite side the transformation of proto-oncogene to fully active oncogenes, such as
c-myc, c-erbB-2, c-yes, c-kit, raf and ras, have been detected in melanomas both in vitro
and in vivo. [2,7] Neoplastic transformation is followed by metastasis, another multistep
process starting with detachment from the primary mass, movement through the
endothelium, travel via blood or lymph, adhesion and exit through the endothelium, and
attachment and proliferation within a secondary site; for which neoplastic cells must
down-regulate and then up-regulate various adhesion molecules (e.g., cadherins, CD44).
[12,13] Finally, at both primary and metastatic locations, the ability to call on
angiogenesis is critical to survival and growth of any neoplasm regardless of its
derivation, including melanomas, in order to support exponential tumor growth. [14]
Evaluations of cultured melanoma cell lines, animal models, and clinical cases are
helping in answering questions regarding both general tumor biology and melanoma
pathogenesis. This disease is becoming one of the fastest growing human cancers
worldwide, experimenting a consistent and dramatic increase in its incidence since the
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1950s (increase which is paralleled by its animal counterpart). [2,15] These type of
tumors also naturally occur in various domestic animal species, such as dogs, cats, angora
goats, cattle, sheep, alpacas, swine and horses. [2]
2. An overview of equine melanoma

Melanocytic tumors have been recognized for centuries in horses and are among
the most common skin tumors noted in this species; comprising between 3.8 and 15% of
all skin tumors, second only to sarcoids. [16-19] According to some studies the incidence
of these tumors in horses in North America may be increasing in parallel with the
incidence of human melanoma.[15,20] A gender predisposition has been suggested, but
not established. [18,21,22] In contrast, while melanomas have been diagnosed in horses
of all colors a marked predisposition has been extensively reported in gray horses, with
prevalence rates reaching as high as 80% in older animals.[18,21-24] Melanocytic tumors
are seldom observed in gray horses less than 5 years of age and congenital tumors are
rare.[21,25,26] Reports of breed predilection have suggested an increased risk for
Arabian, Thoroughbred, Lipizzaner, Camargue and Percheron horses, but this association
may simply reflect the higher number of gray horses in these breeds. [22,27-31] While
melanomas clearly are more frequent in gray horses, they also occur in non-gray horses,
where they are more likely to exhibit malignant behavior. [18]
2.1. Molecular genetic bases of equine melanoma

The increased incidence of melanomas in gray horses has been linked to the
graying process these horses experience around 5 to 8 years of age when they start a
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gradual loss of follicular pigmentation while maintaining a dark skin (Figure2.1). [25,32]
This graying process is an autosomal dominant trait that is associated with an increased
risk of both melanoma and vitiligo.[25,32-34] Studies have been undertaken to elucidate
the molecular basis of the graying process and associated melanocytic tumors as a
comparative model for human melanoma.[34-36] Recent work has identified the genetic
basis for the premature graying as a 4.6-kb duplication in intron 6 of the syntaxin 17 gene
(STX17) which leads to the overexpression of STX17 and the neighboring gene NR4A3.
[32] This duplication also appears to contain regulatory elements that have melanocytespecific effects; transforming a weak enhancer to a strong melanocyte-specific enhancer
that encodes binding sites for the microphthalmia-associated transcription factor (MITF).
[37] MITF regulates melanocyte development and these binding sites within the STX17
gene provide a plausible explanation for the melanocyte-specific effects of the Gray
allele, including hair graying, melanoma susceptibility and vitiligo. While the STX17
mutation is inherited in an autosomal dominant fashion, the risk for melanocytic tumor
formation and the other traits associated with this mutation appear to be polygenic.
[32,37]
The genetics underlying the malignant transformation of melanocytic tumors has
also been investigated. For example, copy number expansion of the STX17 duplication
has been identified within the tumor tissue of grey horse melanoma; the authors have
speculated that the increasing copy number may be associated with tumor aggressiveness.
[38] The Receptor for Activated C Kinase 1 (RACK1), a protein that serves as an
anchoring point for protein kinase C and in this role likely plays a vital part in cellular
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signaling, has also

been associated with melanocytic tumor transformation.

Immunofluorescence studies suggest that RACK1 expression levels can be used to
differentiate between benign and malignant melanocytic tumors. [39]
Mutations in melanocortin-1 receptor (MC1R) signaling have also been studied to
determine their role in melanocytic tumor development. [40-42] Specifically, a single
nucleotide polymorphism in MC1R (C901T) has been linked to chestnut coat color and
resultant low risk of melanocytic tumor development. [41] A loss of function mutation
(ADEx2) in the agouti signaling protein (ASIP), a known antagonist of MC1R, has been
linked to black coat color and an increased risk of melanoma formation. [41] In addition
to the upregulation of downstream genes such as tyrosinase, enhanced signaling through
the MC1R pathway has also been shown to result in markedly increased expression of the
NR4A nuclear receptor subgroup in melanocytic cells. [42] As pointed out previously,
overexpression of NR4A3 has been found in gray horse melanomas; although it has not
been directly associated with the development of melanocytic tumors in humans or
horses. [32,38]
2.3. Pathology and natural behavior

Equine melanocytic tumors have been recognized for centuries as slow growing,
low-grade neoplasms. While the majority of cutaneous melanomas are benign at initial
presentation, if left untreated up to two thirds can progress to overt malignant behavior
capable of extensive local invasion and widespread metastasis. [2,18,22] The most
common external locations for melanocytic tumors include the perineal region, the
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ventral surface of the tail, the prepuce, the commissures of the lips, and the head/neck;
while the parotid salivary gland, ears, eyelids, and limbs are less common sites (Figure
2.2). [18,19,22,43] From these primary locations metastasis may occur by either
hematogenous or lymphatic spread to any region of the body, including lymph nodes and
other cutaneous sites; [18,44] although there is an apparent predilection for the serosal
surface of the spleen, liver and lungs (Figure 2.3). [20,22,43] Major blood vessels
(including the aorta), and even the heart, appear to be other structures commonly
associated with metastatic disease, [43,44] Other reported metastatic locations include the
spinal cord, vertebrae, kidneys, adrenal glands and guttural pouches. [43-47] Rarely,
melanomas may occur solely in visceral locations without any noticeable external disease
sites. [43]
2.4. Tumor Classifications

The term melanocytic tumors encompass all histologic and clinical variants from
the benign melanocytoma (nevus) to the more anaplastic malignant variants. [2] In nongray horses these tumors include only benign and malignant variants. In gray horses,
however, there seems to be a clinical continuum between benign and malignant tumors
and the “melanocytic” disease process is further extended to include hyperpigmentation
and infiltration of the dermis and epidermis resulting in plaque-like lesions rather than
true masses or tumors. [22,47] Tumor histology typically reveals a mildly to moderately
pleomorphic population of neoplastic melanocytes, with an epitheloid to spindle shape,
euchromatic nuclei, rare binucleation, variable and often high cytoplasmic pigmentation,
and occasional mitoses. [2] Tumors in gray horses are classified into distinct histologic
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subtypes based on a combination of tumor cell morphology and location within the
cutaneous adnexa.

Benign-appearing collections of melanocytes located in the

superficial dermis or dermo-epidermal junction are classified as melanocytomas
(melanocytic nevi). Tumors located within deep dermal locations comprised of welldifferentiated melanocytes that exhibit dense cytoplasmic pigmentation and minimal
malignant criteria are classified as dermal melanomas. Dermal melanomas are further
subdivided clinically into those with few discrete nodules and those with a more
disseminated variant with multiple, frequently confluent tumors (dermal melanomatosis)
(Figure 2.2E).

An alternate descriptive classification relies only on tumor cell

morphology and traditional malignancy criteria to group tumors into either benign or
malignant variants. Benign variants contain well-differentiated and heavily pigmented
melanocytes that can exhibit a variable mitotic index and are often contained within a
pseudo-capsule.

Malignant tumors are characterized by increased pleomorphism,

variable pigmentation, moderate to high mitotic rates, evidence of vascular and/or
lymphatic invasion, epidermal invasion, and indistinct tumor margins. [2,18,22]
2.5. Overview of clinical presentation

Cutaneous melanocytic tumors tend to be easily recognizable as darkly pigmented
nodules; however, depigmented areas can often be identified within tumors (Figure 2.2E).
Furthermore, amelanotic or poorly pigmented tumors may occur in both gray and nongray horses. Tumors can be localized in the deeper dermal tissues or may involve more
superficial dermis and epidermal tissue. The latter will often ulcerate through the
epidermis as they progressively enlarge (Figure 2.2F), which can also result in central
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portions becoming necrotic as they outgrow their blood supply. Clinical signs in affected
animals are determined by tumor location. Signs can range from simple interference with
bridle and saddle caused by cutaneous lesions (which can be further complicated by
ulceration and infection) (Figure 2.2F) to more severe signs associated with the local
invasion and the compressive effects caused by internal metastatic lesions.33 Among the
latter weight loss, constipation, impaction and even colic associated with serious
obstructive lesions in the gastrointestinal tract have been reported. [29,43] Furthermore,
neurologic signs including lameness, ataxia, and even paresis secondary to spinal cord
compression by metastatic lesions, and less commonly Horner’s syndrome and unilateral
sweating have also been reported. [43,45-50]
2.6. Diagnosis and workup

The diagnosis of melanoma in equine patients is usually made on the basis of
signalment (gray horse) and the physical appearance of the tumors. In select cases,
including non-gray horses and/or poorly pigmented tumors, biopsy can provide a
definitive diagnosis.

The differentiation between benign and malignant variants is

typically made on the basis of all of these factors in addition to local growth pattern and
the presence/absence of systemic involvement. [18,20,22,43] Molecular tests may also be
useful; [2,38-51] however, their wide-scale reliability for differentiating benign from
malignant tumors has not yet been demonstrated. Diagnostics such as blood work and
imaging are rarely pursued unless specific signs are present that can’t be directly
accounted for by visible tumor burden, such as weight loss, chronic colic, neurologic
deficits, and lameness, amongst others. [43,46] Blood work findings are non-specific and
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may show elevated globulins, increased white cell count, thrombocytosis, or increased
fibrinogen presumably attributed to the inflammatory effects of tumor burden.
Diagnostic imaging can be used to determine the cause of clinical signs, although the
limited number of effective treatment options for internal tumors limits their usefulness.
Rectal palpation can also be useful, especially in patients with perianal melanomas to
assess the extent of these lesions and determine if they may interfere with normal
defecation or could do so in the future.
2.7. Treatment options

Treatment options can be divided into those therapies intended to treat the local
tumor and those meant to treat and/or prevent systemic disease spread. Appropriate
management of advanced cases, however, will require the combination of both
approaches to achieve a successful outcome. Local therapies are used to treat solitary
tumors or control loco-regional disease. Treatments are typically applied directly to the
tumor or into the peri-tumoral tissue. Surgical resection is considered the mainstay of
therapy and is often curative, especially for small benign lesions. In some patients,
however, large tumor size or anatomic location (i.e. parotid region, etc.) may preclude
surgery as a feasible option. Surgery can also be used to debulk more advanced tumors
for palliation of symptoms and can be variably successful. [18,22,43,44,52,53] Radiation
therapy is limited in applicability due to the difficulty in treating large and/or deeply
seated tumors along with the limited availability of this modality in general for equine
patients. [54] Another local therapy that is used very frequently in the case of these
tumors is intra-tumoral chemotherapy, which involves the injection or placement of
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cytotoxic drugs directly into the tumor or peri-tumoral tissue. This approach has the
advantage of delivering high drug concentrations to the tumor (higher than those obtained
by systemic infusion of the same drug) in a cost effective manner while avoiding
systemic drug side effects. Drugs that have been used effectively in horses include
carboplatin and cisplatin. [3,18,44,55] Response rates for equine melanomas treated with
intra-tumoral cisplatin have been reported as high as 81%, and are suggested as to be
inversely related to tumor volume. [55] Chemotherapy can also be delivered into the
tumor through the use of biodegradable drug-containing beads. [56] Other modalities,
including hyperthermia and electrochemotherapy can also be used to increase tumor cell
uptake of chemotherapy and thus improve clinical response (Figure 2.4). [57-63] Another
important form of local treatment is intra-tumoral immunotherapy (which will be
discussed more extensively in section 4.1: Immunotherapy of melanomas in Veterinary
Medicine). A variety of other agents have been anecdotally used to treat melanocytic
tumors. These compounds range from topical 5-Fluorouracil (5-FU) and Imiquimod 5%
(Aldara®) creams to herbal compounds such as XXterra (Larson Labs, Fort Collins, CO)
based in bloodroot powder. Cryotherapy can also be considered as a complementary
measure to sterilize surgical wound beds or to treat small tumors; treatments can typically
be performed in standing sedated horses. [3,18,20,35,53] In comparison to the wide
variety of available local treatment options for horses with melanoma there are few
effective systemic therapies available to treat/prevent disease spread. The only reported
options are immunotherapeutics. Historically this treatment modality has consisted
mainly in the use of the biological immune response modifier cimetidine (with
inconsistent results) [64-69] and more rarely anti-cancer vaccines. [43,70,71] The
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systemic approach to equine melanoma with immunotherapeutics will be discussed more
in depth further ahead.
2.8. Prognosis and comparative aspects

The clinical outcome in horses with melanoma(s) is mainly determined by initial
tumor size and extent. [2,22] Histopathological classification and availability of treatment
options also has some impact. [2] In general, melanomas in gray horses expand slowly or
may show tumor dormancy for long periods, even years. If left untreated many will
eventually acquire malignant clinical behavior with respect to both local growth and
systemic spread. [18] Ultimately, the time from tumor appearance and/or diagnosis to the
time that advanced loco-regional or systemic disease is diagnosed will vary from animal
to animal and no formal survival time studies have been performed in the horse. In both
humans and dogs, malignant melanomas may result in widespread life-threatening
metastases; however, unlike in humans most horses will not die from metastatic disease
but are euthanized due to local disease complications (e.g., large peri-anal melanomas
that prevent normal defecation or rupture, get ulcerated, infected and painful). Systemic
signs associated with advanced metastatic disease in both humans and horses are varied,
including: chronic weight loss, neurologic symptoms, and respiratory signs amongst
others. Some of the more common equine specific signs associated with advanced
disease include colic symptoms from gastrointestinal invasion, difficulty defecating from
obstructive lesions, nasal bleeding or neurologic signs from guttural pouch involvement.
When such advanced symptoms are observed in horses they can be difficult to treat and
will commonly be the cause of death or reason for euthanasia. The development of new
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local and systemic therapies, including advances in accessible radiotherapy and
molecularly targeted therapies will prove useful in managing these challenging cases.
3. Main Concepts on Immunology of Melanocytic tumors

The immune system is not only capable of protecting us from foreign invaders,
such as bacteria, parasites, viruses and other infectious agents; it also monitors for the
appearance of more “internal aggressors”, from which neoplastic cells are the more
infamous examples. The idea that the immune system may actively prevent and even
eliminate the development of neoplasia is termed cancer immunosurveillance [72,73] and
is the fundamental rationale for immunotherapy for cancer.[74] A long line of laboratory
evidence support this hypothesis, including the findings that IFN-γ protects mice against
the growth of tumors and that mice lacking IFN-γ receptor are more sensitive to
chemically induced sarcomas and are more likely to spontaneously develop tumors.[75]
Multiple lines of evidence support also role for the immune system in clinically
managing cancer, including (1) spontaneous remissions in cancer patients without
treatment; (2) the presence of tumor-specific cytotoxic T cells within tumors or draining
lymph nodes; (3) the presence of monocytic, lymphocytic, and plasmacytic cellular
infiltrates in tumors; (4) the increased incidence of some types of cancer in
immunosuppressed patients; and (5) documentation of cancer remissions with the use of
immunomodulators. [76-79]
But despite this constant surveillance, as we all know, tumors do occur in
immunocompetent individuals. There are not only significant barriers to the generation of
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effective antitumor immunity by the host, but also many tumors evade surveillance
mechanisms and so are able to grow in immunocompetent hosts, which is shown by the
large numbers of people and animals succumbing to cancer. There are several ways in
which tumors can do this: (1) by production of immunosuppressive cytokines (e.g. TGFβ and IL-10); (2) by impairing DC function, activationand/or maturation; (3) by induction
of regulatory T cells, which can suppress tumor-specific CD4/CD8+ T cells [11]; (4) by
promoting MHC I loss through structural defects, changes in B2-microglobulin synthesis,
defects in transporter-associated antigen processing or actual MHC I gene loss; among
many other mechanisms. [73,80,81]
Nonetheless with the tools of molecular biology and a greater understanding of
mechanisms to harness the immune system, effective tumor immunotherapy is becoming
a reality. [82] This new class of therapeutics offers a more targeted, and therefore precise,
approach to the treatment of cancer. [83] It is likely that immunotherapy will eventually
have a place alongside the classic cancer treatment triad components of surgery, radiation
therapy, and chemotherapy. [84,85]
3.1. Are melanomas immunogenic tumors?
Melanoma is possibly the best example of an “immunogenic” tumor. Virtually all
the major principles of “tumor immunology” have been experimentally established in this
model (for reasons not entirely clear but perhaps because melanoma cells could be
cultured with relative ease, a good deal of the work on tumor immunity was conducted in
the melanoma model). [86] This tumor type exhibit a set of unique features strongly
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suggestive of “footprints” of host immune responses. Among the clinical features that
have long been associated with melanoma and are suggestive of some form of host
immune responses against this disease are: (1) primary melanomas at times
spontaneously undergo partial or complete regression; (2) primary melanomas often
exhibit strong lymphocytic infiltrations, both immunosuppressive (with regulatory T
cells, associated with a worse prognosis) as well as immunepotentiating (with cytotoxic T
cells, associated with a better prognosis); (3) nevi at times show a ring of depigmentation
around them; (4) primary melanomas also often show areas of depigmentation; (5)
development of vitiligo carries a good prognosis in patients with melanoma. Although
these features, by themselves, do not prove that spontaneous regression, halos,
depigmentation, or a relationship between vitiligo and good prognosis represent
unequivocal evidence of host immune responses, the idea that human melanoma is an
immunogenic tumor gets considerable support from laboratory observations that have
shown (1) the infiltrating lymphocytes are mostly α/β T cells, custodians on cell-mediated
immunity; (2) regressing melanomas show evidence of clonal amplification of T cells, in
situ; and (3) T cells isolated from regressing melanomas exhibit cytolytic activity against
autologous melanomas. [77-79,86]
It is now amply clear that melanoma cells display multiple antigens and peptide
epitopes that are targetable by the host immune system and that patients with melanoma
are capable of responding to these antigens and epitopes serologically (it has largely been
shown that patients with melanoma are capable of producing IgM and IgG antibodies
against cell surface–associated antigens on autologous melanoma cells [87]) as well as
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through the cell-mediated mechanisms (various experiments using microcytotoxicity
assays and T-cell cloning technology, among other techniques have shown that
melanoma-bearing hosts do indeed harbor a cytotoxic CD8 T cell population capable of
selectively recognize and target for destruction autologous tumor cells expressing
melanoma-associated antigens in a MHC-I manner [88], as well as a CD4 T cell
population capable of recognizing melanoma-associated peptide epitopes processed and
presented in an MHC class II–restricted manner by APCs, elaborate and secrete a number
of inflammatory cytokines to help the expansion of the previously mentioned CD8+ T
cells [89], and also a NK cell population capable of killing melanoma cells that have lost
completely or partially MHC expression [90]).
3.2. Melanoma-Associated Antigens: The key elements for immune response

Among the tumor associated antigens that melanoma cells display the most
widely studied in the context of tumor immunology and immunotherapy are melanocyte
differentiation antigens (or MDA). [91] Differentiation antigens are proteins that
distinguish a cell linage from another, and are typically expressed at specific stages of
differentiation; in the case of melanocytes these are called melanocyte differentiation
antigens and are mostly proteins logically involved in a process that only this cell type
carries away: the synthesis of melanin (Figure 2.5). [92] And so these proteins are almost
exclusively expressed by melanocytes (these can also be expressed in some CNS cells,
with which they share the same neuroectodermal origin). [93] Moreover, although both
normal and malignant melanocytes expressed these antigens, several studies (including
our own in canine and equine melanomas) have shown that they are overexpressed in
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malignant tissue in comparison to normal tissue [70,93]. Amongst the most important
melanocyte differentiation proteins are:
Tyrosinase: a crucial enzyme that functions to catalyze the hydroxylation of tyrosine
to dihydroxyphenylalanine (or DOPA) and subsequent oxidation of DOPA to
DOPAquinone, the initial and rate limiting step in the cascade of reactions leading to
melanin synthesis. This is also the tyrosinase family’s protomolecule, being that all
other proteins in the family show a 50% homology to it. [94]
Tyrosinase Related Protein 1: also known as TRP1 or gp75, part of the tyrosinase
protein family, modulates tyrosinase catalytic activity, maintains melanosomal
structure and to some degree even affects melanocyte proliferation and death. [95]
Tyrosinase Related Protein 2: part of the tyrosinase protein family, also known as
TRP2 or DOPAchrome tautomerase, being that it mediates the transformation of the
pigmented intermediate DOPAchrome to DHICA (5,6-dihydroxyindole-2-carboxylic
acid) rather than to DHI (5,6-dihydroxyindole), which would be generated
spontaneously and so catalyzes the late step in eumelanin formation. [96]
Melanomsomal membrane glycoprotein 100: also known as gp100 or PMEL; is a
transmembrane glycoprotein enriched in melanosomes and involved in their
maturation serving as a structural component of the melanosome fibrillar matrix upon
which melanins are deposited. [97]
Melanoma Antigen Recognized by T-cells: also known as MART-1 or Melan-A
bounds to MHC class I complexes which present it to T cells of the immune system.
These complexes can be found on the surface of melanoma cells (reason why they are
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also useful for the histopathologic diagnosis of melanocytic tumors). It also regulates
melanosome fibril formation. [98]
These proteins are mostly melanosomal membrane surface proteins, which means
that they are mostly expressed intracellularly [99], so making them a harder target for the
immune system to home in in the context of cancer immunotherapy. TRP1 or gp75 serves
as a good example of the intracellular distribution pattern these melanosomal proteins
tend to follow. This protein is first synthesized in the endoplasmic reticulum, then
transported through the Golgi complex (where it gets glycosylated), and finally sorted to
the endosomal compartment and to melanosomes. Furthermore, it contains an
intracellular retention signal that sorts it to the endosomal compartment, leading to stable
intracellular retention. [100] And while one can understand how T cells can respond to
intracellular proteins, based on cellular requirements for antigen processing and
presentation (part of the normal monitoring to which all cellular inner-proteins are
subjected via an MHC-1 associated immunosurvailance mechanism) [86], it is more
difficult to understand how antibody responses to melanosomal proteins could lead to
tumor rejection. However, a study by Takechi, et al. which tried to approach this problem
surprisingly demonstrated that TRP1 can and is fact expressed on the cell surface as well
as intracellularly in human and mouse melanomas. [101] In this study various melanoma
cell lines, both murine (Bl6FlO) and human (SK-MEL-l9 and SK-MEL-23), were
analyzed by MHA assays using a specific mAb and showed that this protein also reaches
the plasma membrane, results which were further confirmed by flowcytometry. Other
studies have also shown evidence that these proteins can also be expressed in some
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occasions and in low levels of expression at the cell surface. [102] Thus, despite the
presence of an intracellular retention signal within the TRP1 protein, a proportion of it
does reach the cell surface. If this co-localization pattern presents as well with other
members of this family it can only be assumed so far and further studies are warranted.
Studies dealing with melanoma immunology and immunotherapy have shown
over and over that the immune system can and does recognize these particular proteins
and is able to mount a specific cellular and humoral response based on them
[93,101,102]. Although, these melanocyte differentiation antigens are not likely
implicated directly on malignant transformation, their exclusive expression pattern marks
them as very useful potential targets usually used the immunotherapeutic treatment of
melanomas in both human and veterinary medicine. [70,93]
Needless to mention, the list of melanoma antigens for CD8 T cells as well as for
CD4 T cells continues to expand at a steady pace along with continued interest in
melanoma immunotherapy. Melanoma immunology is no longer simply restricted to
studying the topic at the bench. Virtually all the observations made at the bench have now
been translated in the clinic and intense effort is under way to make cancer
immunotherapy, in general, and melanoma immunotherapy, in particular, more effective
[86].
4. Immunotherapy as a treatment option for melanomas

Due to the inherent immunogenicity associated with melanocytic tumors, the
increasing knowledge accumulated over the years on melanoma-associated antigens and
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epitopes, the progress in methods of anti-cancer immunization techniques and
technologies for generating melanoma antigen-specific T cells, and the fact that the bases
of both general tumor immunology and immunotherapy are built around research
performed in this particular tumor type it is not at all surprising the large number of
immunotherapeutic strategies and drugs developed over the years in an attempt to harness
and aim the power of the immune system at this tumor type. [84,86] Although these
strategies have not been uniformly successful in all cases, durable complete regressions
have been obtained in the past, this coupled with the most recent developments in
monoclonal antibody-based immune modulation show reason for hope that continuing
research in the field is likely to improve the outcome of melanoma immunotherapy: the
ultimate goal of tumor immunology. [83-85,104]
4.1. Immunotherapy of melanomas: The human medicine side

Current cancer immunotherapy for melanoma in the context of human medicine
consists of regimens involving IL-2, interferon, targeting of the inhibitory receptor CTLA
‑4, or inhibiting the interaction of PD-1 ligand with its receptor. [83] IL-2 therapy has
shown little improvement in overall patient survival; although interferon was shown to
improve relapse-free and overall survival, it is also associated with an extensive set of
side effects. [105] IFN treatment is the most studied and only approved adjuvant therapy
for melanoma patients, as well as the first agent to show a significant benefit in relapse
free survival and OS of high-risk melanoma patients. [106] Melanoma vaccines, although
showing great promise, have so far failed to demonstrate a significant therapeutic effect.
[107] Adoptive T-cell therapy, although quite complex, has shown strong clinical
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response rates. But this treatment is both cost-prohibitive and time-consuming, thus
limiting its general applicability. [108] But it was not until 2010/2011 that, thanks to a
more in-depth understanding of the molecular and immunological background of the
disease, the next landmark in the treatment of melanoma was achieved; and after a very
successful phase III trial the fully human cytotoxic T-lymphocyte-associated antigen-4
(CTLA-4) blocking monoclonal antibody Ipilimumab was approved for use in patients
with refractory metastatic melanoma. [109,110] This new agent has resulted in a
substantial improvement in the median overall survival in patients with previously treated
melanoma. [111] Furthermore, on the same lines as Ipilimumab, treatment of the effector
phase of the immune response, through PD-1 inhibition (Nivolumab), has resulted in high
objective response rates in clinical trials and shows great promise for more general use.
[112]
4.2. Immunotherapy of melanomas in Veterinary Medicine

As it can be seen, with the appearance and promising results obtained with
monoclonal antibody-based immune modulation (Ipilimumab and Nivolumumab), as
well as the also great results obtained with the BRAF kinase inhibitor Vemurafenib the
management of human melanoma bearing patients is clearly tilting towards the use of
small molecules and monoclonal antibodies, as it should. [109-113] But this type of
therapy remains non-applicable in veterinary medicine for mainly two reasons: (1) all
these monoclonal antibodies are design specifically for human patients (which would
render them ineffective after the first doses in another species, when their immune
systems starts elaborating nullifying antibodies to the drug) and currently there are no
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monoclonal antibodies designed for the treatment of this tumor type in veterinary
patients; (2) all these drugs would be cost prohibited for the grand majority on pet
owners.
Still, the necessity for effective systemic therapies for this disease in veterinary
patients remains, specially taking in account that these tumors show a remarkable (both in
human and veterinary patients) unresponsiveness to the more conventional forms of anticancer therapy, such as chemotherapy and radiotherapy. [114-116] Is in this context that
immunotherapy rises up as a potential systemic therapeutic strategy for melanoma.
Without a doubt almost all the work done in pet melanoma immunology and
immunotherapy has been done in dogs primarily and in horses secondarily (both niches
where this disease, due to its aggressiveness and high prevalence respectively, remains of
particular importance). Immunotherapy strategies to date in canine melanoma have used
autologous tumor cell vaccines (with or without transfection with immunostimulatory
cytokines and/or melanosomal differentiation antigens), allogeneic tumor cell vaccines
transfected with interleukin-2 or GM-CSF, liposomal-encapsulated nonspecific
immunostimulators (eg, L-MTP-PE), intralesional Fas ligand DNA, bacterial
superantigen approaches with granulocyte macrophage colony-stimulating factor or
interleukin 2 as immune adjuvants, and last, canine dendritic cell vaccines loaded with
melanosomal differentiation antigens. [117-122] Although these approaches have
produced some clinical antitumor responses, the methodologies for the generation of
these products are expensive, time-consuming, sometimes dependent on patient tumor
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samples being established into cell lines, and fraught with the difficulties of consistency,
reproducibility, and other quality-control issues. [117,123]
The advent of DNA vaccination circumvents some of these previously
encountered hurdles. And so, in 2007 the USDA conditionally approved the first anticancer vaccine ever designed and marketed to treat a malignancy in veterinary patients, in
this case malignant melanoma in dogs. This conditional license was later granted full
licensure in 2010. This vaccine is the final product of a long line of research in melanoma
immunology and immunotherapy and of the strategic venture between two well
renowned medical institutions: The Memorial Sloan-Kettering Cancer Center on the
human medicine side and The Animal Medical Center on the veterinary side, both based
in New York City. [123] Several studies performed since have ratified the effectiveness
of this immunotherapeutic modality in canine patients with melanoma, for whom it has
consolidated into the only effective systemic treatment for the management of this
disease, considerably increasing patient’s survival time and revolutionizing how the
disease is both approached and treated. [124-127]
In the particular case of horses suffering from melanocytic tumors, although
considerable effort has been placed in the last three decades in trying to understand the
hereditability and molecular basis of this disease [25-42,128] and although this
understanding is definitely the base for the development of new therapies, few tangible
advances have been made to date in matters of how to effectively treat this disease.
Nonetheless, immunotherapeutic approaches have also been implemented in this species
over the years in an attempt to control both the local and systemic components of their
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disease. Unfortunately most of these have failed to show significant or reproducible
results. Local immunotherapy has mainly been limited to direct intra-tumoral injections
with the biologic immune response modifier Bacillus Calmette-Guerin (BCG) [18] or
with plasmids encoding the cytokines Il-12 and Il-18. [128,129] These cytokines have
anti-tumor effects through the activation of cytotoxic T cells, the production of
interferon-γ, and the induction of apoptosis in tumors cells. [130] Two studies evaluated
the use of these agents in tumor-bearing gray horses. The first study involved the intratumoral injection of DNA plasmids encoding the human Il-12 gene in a cohort of 7 gray
horses. [128] The other study involved the intra-tumoral injection of DNA plasmids
containing either equine Il-12 or Il-18 in a cohort of 26 gray horses. [129] Shrinkage of
the injected tumors was observed in the majority of horses from each study and the
therapy appeared to be safe and well tolerated. Unfortunately, although these plasmids
have shown activity, these treatments are not commercially available and their benefits
appear to be limited to injected lesions (i.e. no systemic anti-tumor effects). Results from
intratumoral injections of BCG in equine melanomas have been disappointing. [18]
Attempts to try to control the systemic component of this disease have historically been
limited to the use of the unspecific biologic immune response modifier cimetidine.
Cimetidine is a well-known histamine (H2) receptor antagonist that may exert anti-tumor
effects by several mechanisms including the inhibition of H2 receptors on tumor cells as
well as the “immune stimulatory” effects of activating natural killer cells and the
blocking of H2 receptor mediated activation of immunosuppressive regulatory T cells.
[131-136] Although one small case series has described a clinical benefit in treated
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horses, [133] several larger clinical trials have failed to replicate these results62-64 and
thus the clinical effectiveness of cimetidine immunotherapy remains questionable.
As it can be observed the treatment of melanomas in horses to this date remains
mainly limited to attempts to control the local component of the disease (e.g., surgery,
intratumoral chemotherapy); while its systemic aspect is left free to run unchecked and
progress at its own pace; most of the time being approached by either a questionable
therapy as cimetidine or most commonly by simple benign neglect.
5. Anti-melanoma Vaccines

Cimetidine, IL-12, IL-18 and BCG are all examples of non-specific tumor
immunotherapy. This type of immunotherapy do not directly target tumor cells or tumor
related antigens; rather they stimulate the immune system in a general way that may also
result in increased activity against tumors. This less selective, more general, harnessing
of the power of the immune system is logically associated with a higher risk of important
adverse events and toxicity. Tumor-specific immunotherapy, on the other hand, refers to
the selective modulation of the immune response so as to cause specific destruction of the
malignancy with minimal systemic side effects and cross-reactivity to normal cellular
components. In this immune anti-cancer approach specific tumor associated antigens
(TAA), which are proteins that are preferentially expressed or overexpressed in tumor
tissue, are directly targeted. This preferential expression may occur either in a temporal
or spatial fashion and so allowing for the targeting of tumor tissue while sparing normal
tissue. An example of temporally restricted expression is a tumor that expresses an
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embryologic antigen in an adult animal (Ex: CEA in human colon cancer). A spatially
restricted protein is one where the expression is limited to tumor tissue with minimal to
no expression in other tissues. And so these antigens are used to hone the immune
system into attacking the cells that preferentially or abnormally express them with the
ultimate goal of elicitating an antitumor immune response that results in clinical
regression of a tumor and/or its metastases. [137,138]
Identification of these proteins allows for the creation of immunotherapeutics or
“vaccines” designed to elicit specific immune responses against cells that contain them
regardless of their location within the body. [107,123,137-139] At the start of the 20th
century, encouraged by the success (high efficacy and low toxicity) in immunizing
against infectious diseases such as smallpox, rabies, cholera, and anthrax, investigators
and physicians began trying to immunize patients against cancer. This was done at the
time with little understanding of the nature of malignancy or of the immune system. Over
the past several decades, we have begun to unravel the complexities of the immune
system, and his complicated relationship with cancer. [140] The earliest melanoma
vaccines were formulated from autologous or allogeneic melanoma cells. Subsequently,
molecularly defined vaccines made from proteins, peptides, or gangliosides were
developed and, more recently, DNA-based vaccines started to be tested. A summary of
the advantages and disadvantages of each type of vaccines are summarized in Table 2.1.
[29,107,141] But regardless of type the ultimate goal of all “cancer vaccines” is the
generation of an antitumor immune response that results in clinical regression of a
primary tumor and any associated metastatic lesions. [139-141]
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From all these types of cancer vaccines, by the time of this project, only one type
have been specifically used for the treatment of equine melanoma; namely, whole-tumor
cell autogenous vaccines [43,71] Autogenous vaccines are created by isolating cells from
the excised tumor of an individual equine patient, which are then processed in vitro into a
vaccine formulation, and then readministered to the same patient. There are two reports
describing the use of authogenous vaccine in melanoma-bearing horses. [43,71] Tumor
regressions and subjective improvement in well-being were reported in both studies.
Unfortunately, the studies involved relatively small numbers of horses who were also
treated with more than just the vaccine and thus the true benefit of these autogenous
vaccines remains unknown.
6. DNA vaccines and Merial’s Ltd. Human Tyrosinase Oncept® DNA Vaccine

Unlike autogenous vaccines, DNA-based vaccines are created by first identifying
an appropriate tumor associated antigen. These antigens are tumor-specific proteins
whose DNA sequence is used to create the vaccine. The DNA sequence is typically
cloned into a molecular vector that allows for the in vivo expression of the encoded
protein. [140,141,142] Most molecular vectors also have immune stimulatory properties
that improve the efficiency of the vaccine in generating an immune response against the
expressed protein. [142,143] This molecular construct (i.e. DNA sequence cloned into
vector) is often administered to the patient by intramuscular injection and thus resembles
a “vaccination”; although may be more appropriately referred to as gene therapy. DNA
vaccines possess many advantages over other vaccine types, being the main ones that the
whole DNA sequence of a target protein can be inserted in the plasmid, which would lead

32

to the expression of numerous epitopes (and not limited to just one as with peptide based
vaccines), immunostimulatory sequence can also be inserted on the plasmid (which
enhances immune response and reduces the need for adjuvants as in also the case of
peptide vaccines), yet they remain relatively simple to prepare (Table 2.1). [29,107,141]
One logical tumor associated antigen that can be targeted in melanomas via a
DNA-based vaccine is the melanocyte differentiation antigen tyrosinase glycoprotein; an
enzyme crucial for melanin pigment synthesis, as mentioned before. Tyrosinase has the
ideal characteristics for a tumor associated antigen because its expression is virtually
limited to melanocytes. [94] Furthermore, in melanomas (including equine variants) the
tyrosinase expression appears to be constitutively increased compared to normal
melanocytes. [144] A USDA-approved xenogenic DNA vaccine encoding human
tyrosinase (HuTyr) is available for treatment of canine melanoma (Oncept; Merial, Ltd.
Athens, GA). [145] This vaccine exploits the close homology (92%) between human and
canine tyrosinase to generate a tyrosinase-specific anti-tumor response and dramatically
improves survival in treated dogs. [146] In comparison, the equine tyrosinase sequence
shares 90% homology to the human sequence; based on this, cross reactivity of HuTyr
DNA vaccine in the horse would be expected.
6.1. The road to a vaccine (Oncept®): from mice to men, to dogs and to horses

This tyrosinase xenogeneic DNA vaccine is the end product of a long line of
research in human and animal melanoma immunology and immunotherapy. With most of
the basic research (i.e., preliminary in vitro studies and trials using murine models of
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melanoma) that more directly paved the road that lead to the development of this vaccine
being performed by Doctor Jedd Wolchok’s group at the Memorial Sloan-Kettering
Cancer Center (MSKCC) in New York.
By 1998, in some of their earliest work, Doctor Wolchok’s group at the MSKCC
utilizing a murine model of melanoma showed that tolerance to a melanocyte
differentiation antigen or MDA (in this case GP75/TRP1) could be broken by using DNA
from one species to vaccinate another one in an immunotherapeutic strategy known as
“xenogeneic vaccination”. In this study a human GP75/TRP1 DNA vaccine was used for
immunization. Here the induction of tumor immunity and autoimmunity (in the form of
vitiligo-like areas of depigmentation) were associated with an increase in autoantibody
levels. Furthermore, this study also hinted the advantages of another important
immunotherapeutic strategy known as “prime and boosting”, entitling the combination of
both xenogeneic (prime) and syngeneic (boost) vaccination consecutively in the same
immunization schedule, a strategy used to help in breaking of immune tolerance. [147]
The advantages of xenogeneic over syngeneic vaccination as a way of breaking immune
tolerance to self-proteins, was also observed in a following study (1999) by the same
group using the same murine model of melanoma and immunization method (xenogeneic
DNA vaccination), but with a different MDA. This time the MDA used was human
TRP2. In contrast to immunization against GP75/TRP1, both tumor immunity and
autoimmunity to TRP2 required CD8+ T cells, but not antibodies. Thus, these two
consecutive studies also helped to evidence that the immunity induced against two
closely related autoantigens (TRP1 and 2), both highly conserved throughout vertebrate
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evolution, can involve qualitatively different mechanisms (i.e., antibody versus CD8+ T
cell); but lead both to tumor immunity and identical phenotypic manifestations of
autoimmunity. Furthermore, this latter study also hinted the usefulness of biologic
adjuvants, in this case granulocyte-macrophage colony stimulating factor (GM-CSF), as
means to further boost the strength of the elicited immune response. [148] This role of
GM-CSF as a vaccine adjuvant for plasmid DNA vaccination was evaluated further in
another subsequent study (2000) by this same group. In it the pretreatment with GM-CSF
plasmid DNA before immunization with xenogeneic human GP75/TRP1 plasmid DNA
not only notably accelerated the generation of antigen specific antibodies, but also
considerably increased protection from tumor challenge in their murine melanoma model.
In other similar studies this adjuvant was cloned onto the same DNA plasmid and coexpress with the MDA (MAGE-1), effectively enhancing tumor immunity. [149] The
necessity of vaccine adjuvants mainly resides in the poor immunogenicity that generally
characterizes all self-proteins, such as these MDAs. Doctor Wolchok’s research team at
the Memorial Sloan-Kettering Cancer Center would later in the same year (2000)
corroborate once again the superiority of xenogeneic immunization over syngeneic
immunization using their murine melanoma model and a plasmid DNA vaccine coding
that time for gp100, another known MDA. [150]
With all this background knowledge and experience in laboratory murine models
of melanoma and the treatment of their induced condition with MDA vaccines is that
Doctor Wolchok’s group decides to finally make the jump from the artificial melanomas
induced in mice to the natural occurring melanomas of dogs. This is a logical step if
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taken in account that no induce model of cancer will ever show the wide cellular,
molecular and immunological heterogeneity that naturally occurring cancers have, which
is of particular importance in the context of targeted therapy. And this is how in 2003
Doctor Wolchok’s group at the MSKCC pursued a strategic partnership with the
veterinary oncology department at the Animal Medical Center (AMC), both very well
renowned institutions in their field and both located in the New York city area. To this
This partnership was immediately symbiotic, and took advantage of the fact that dogs
were a far better model for human melanoma than mice on one side and that at the same
time it could potentially provide a greatly needed systemic therapy for this disease in
dogs.
By the time of the initiation of the veterinary canine melanoma studies in 2003,
several decisions had already been made based on the previous murine studies. It was
well established for example that a xenogeneic target antigen would be chosen over a
syngeneic one and that a protein from the tyrosinase family would be used as a target.
But despite the fact that most of Wolchok’s job was done using tyrosinase related
proteins, either TRP1 or TEP2, it was tyrosinase, (the family’s protomolecule) the one
selected for the job.
This protein was selected despite the fact that before our tyrosinase mRNA
expression study in dogs and horses with melanoma [144], tyrosinase expression (least
alone overexpression) had never truly been demonstrated in canine melanomas, [151] and
that most work in the human field at the time was done using tyrosinase related proteins,
especially TRP2, but not tyrosinase itself. [152,153] But at the same time this was still

36

the family’s protomolecule and had a huge deal of research behind it supporting its
homogeneous expression pattern in human melanomas. [154]
The first official work with this xenogeneic human tyrosinase plasmid DNA
vaccine in canine tumor bearing patients was published in back in 2003 by a combined
effort of Dr. Bergman’s group at the AMC and Dr. Wolchok’s group at the MSKCC. At
this point in time in the development of this vaccine a third and key partner also had join
this efforts: Merial Ltd, a pharmaceutical company with a large history and experience in
developing immunotherapeutics, and especially vaccines. They developed and provided
the pING plasmid vector that was used a vehicle to generate and deliver this vaccine
(Figure 2.6). This first formal study described a phase I clinical trial using escalating
doses of this vaccine on a small canine population with advanced melanoma. Overall
these dogs experienced a median survival time of 389 days, which was a dramatic
increase in the historical survival time for this disease in dogs (most dogs with advanced
oral malignant melanoma had a median survival time of only 60-90 days with the
therapies available at that time). Importantly too, this population did not experienced any
important side effects from treatment. This study also described for the first time the
usage of the needle-free injection device now widely used to administer this vaccine in
veterinary medicine.[124] In 2006 the same group published went back to revise other
potential vaccine immunotargets in a dose escalation study using plasmid DNA coding
for several different molecular targets including xenogeneic tyrosinase DNA from two
different sources, (murine and human), murine GP75, human GM-CSF or a combination
of the last two to treat oral malignant melanoma in tumor bearing canine patients. In this
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study it was the dogs being treated with HuTyr the ones that appeared to have the longest
median survival time (MST) of all the groups, a very significant increase over the
historical MST for dogs suffering from this disease, making stronger the case for the
selection of tyrosinase as the protein of choice for this immunotherapeutic in the
making.[125] A later expansion of this work was published in the same year but in a
different journal and investigated the characteristics of the antibody response elicited by
this HuTyr vaccine in the tumor-bearing treated dogs. This report documented for the
first time in canine patients the induction of tyrosinase-specific antibody responses, as
well as the identification of cross-reactions with syngeneic canine tyrosinase,
demonstrating the ability of this vaccine to overcome host immune tolerance and/or
ignorance to or of "self" antigens. [155] The results of these trials performed up to this
point had demonstrated that xenogeneic DNA vaccination in the context of canine oral
malignant melanoma was: (1) safe, (2) leads to the development of anti-tyrosinase
antibodies, (3) is potentially therapeutic, and (4) is an attractive candidate for further
evaluation in an adjuvant, minimal residual disease Phase II setting for canine malignant
melanoma. And so, as mentioned before, in 2007 the USDA conditionally approved this
xenogeneic human tyrosinase DNA vaccine as the first anti-cancer vaccine ever designed
and marketed to treat a malignancy in veterinary patients [145], in this case malignant
melanoma in dogs. This conditional license was later granted full licensure in 2010.
Based on the success of this therapy in treating oral canine melanoma the same
group decided to look also at digital melanoma, another common and also very
aggressive form of these tumors in dogs. And so they conducted a retrospective study

38

including 58 dogs suffering from this particular form of melanoma, and treated with a
xenogeneic tyrosinase vaccine (in this case murine, not human DNA was used). The final
paper was published in 2011 and showed this vaccine as being safe and effective when
used in conjunction with local and regional disease control.[126]
A final study by scientists from all three collaborating institutions (The MKSCC,
The AMC and Merial Ltd.) was published that same year. It had the objective of
evaluating safety and clinical efficacy of this HuTyr vaccine to treat oral malignant
melanomas in a bigger population of affected dogs (59 prospectively included dogs and
58 historical controls), at a standardized dose and vaccination schedule and in the proper
context: advanced but locally controlled disease. This study once again showed a
significant increase in survival time in dogs under therapy in comparison to historical
controls, supporting the safety and efficacy of this immunotherapy in the context of
canine oral malignant melanoma. [127] To this day this therapy also continues to be
explored by Dr. Wolchok’s group as a viable treatment for human melanoma. [156] And
so, although a most recent retrospective study failed to see a benefit from this treatment,
this long line of research presented here greatly supports its usage. [157] And there is no
doubt that this therapy has to this day greatly revolutionized how veterinarians approach
and treat this disease in dogs, and hopefully at the end of the present study it will do the
same for horses suffering from this disease.
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6.2. Mechanism of action of DNA vaccines and Oncept®

To exert their action DNA vaccines have to first reach their site of action.
Vaccinate is delivered to its selected site of action using a particular delivery mechanism.
Among the mechanisms available to deliver DNA vaccinates are, among others, the use
of gene guns, topical application, needle injection and in the case of Oncept® the use of a
needle-free injector. Each one of these delivery methods introduce the vaccine to distinct
areas of immune surveillance network and therefore prime the immune system in
different ways. When comparing a simple needle injection with a needle-free injection,
although the former is simpler it can only result in the uptake of the vaccinate by the cells
in the vicinity of the inserted needle; while the use of a needle-free intramuscular
injection device (like the one used to deliver the Oncept® HuTyr vaccine) allows for a
painless injection with a wider distribution range of vaccinate. This wider distribution
range increases the chances of this injectate to enter in contact with a larger number of
antigen presenting cells and so increases the chances and intensity of an anti-tumor
immune response to the vaccine. [159] Through the use of needle-free injection device
vaccines can be selectively delivered to either the skin or muscle tissue, by varying some
physical characteristics of the device itself (e.g., nozzle longitude, nozzle diameter,
injection pressure, stand-off distance).[144,160]
Among the sites chosen for delivery of plasmid DNA vaccinates, the skin and the
muscle are the most common selected target tissues, each one with its own sets of
advantages and disadvantages. [159,161] While intradermal injection results in direct
transfection (i.e., process of deliberately introducing nucleic acids into cells) of mainly
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skin fibroblasts and keratinocytes; intramuscular injection results in transfection of
mainly myocytes. Nonetheless most of the extent of the protection elicited by these
various modes of vaccine administration is determined most likely by the quality and
quantity of the network of APCs residing in the target tissue. For example, the skin in
comparison to the muscle not only exclusively contain Largenhans cells (very powerful
APCs) but counts with more APCs altogether, so less DNA may be required to induce a
response of the same magnitude in the former than the latter. Nonetheless, inoculation in
different sites generates immune responses of different nature, greatly depending on the
particular network of cells residing in the selected target tissue that will be able to present
the vaccine antigen. And so, APCs and cells acting as APCs (e.g., keratinocytes in the
skin and myocytes in the muscle) transfected at different locations seem to be
functionally distinct and therefore prime the immune response uniquely. And so, it has
been shown that while intradermal inoculation tends to result in the induction of a
primarily humoral response or type Th2; intramuscular injections result in the induction
of a strong cellular mediated response or type Th1 that primes antigen specific CTLs. In
the context of anticancer vaccination it is now well accepted that it is the induction of a
potent cellular immune response with the development of a CTL population specific for
the TAA, more than a humoral response, which more importantly mediates tumor
regression (especially for intracellular TAAs such as tyrosinase), and constitutes the end
goal on any anticancer vaccine. Under this notion, the muscle was selected as the optimal
injection site for the Oncept® anti-melanoma plasmid DNA vaccine in dogs and horses.
[124-127,144]
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Although there has been much speculation regarding the mechanisms underlying
DNA vaccine function, these remain complex and have yet to be fully elucidated. In the
case of Oncept® the injectate is delivered using a needle-free device into the muscle,
once in there the plasmid DNA vector construct is going to be uptaken and transfected
mainly by muscle cells. This will also occur in the resident professional APCs that are
present at the injection site at the time of vaccination, but their number in this tissue is
considerably smaller. Once inside the myocytes the intracellular transcription and
translation of plasmid DNA are thought to mimic the replication of a virus during
infection. The powerful viral promoter inserted into the plasmid DNA construct uses this
somatic cell’s own translational machinery to encode the protein target specified on the
transgene sequence (also inserted in the plasmid), in this case tyrosinase. This
intracellularly synthesized plasmid product, as any intracellular peptide subject to
immune surveillance, enters then to the endogenous MHC-I mediated antigen
presentation pathway. Through it these peptide products are first transported, via the
protein transporters associated with antigen processing (TAP)-dependent system, into the
endoplasmic reticulum (ER) where are further trimmed by local aminopeptidases to
produce peptides of 8–10 amino acids, and then associated with MHC-I molecules. These
MHC-I/antigen complexes are then released from the ER and proceed to the Golgi
complex for final processing and packaging to finally be set on their way to be presented
at the cell surface to the immune cells. Furthermore, a percentage of this translated
vaccine antigen product is instead secreted into the extracellular compartment, where
APCs may proceed to phagocytize it. This way the vaccine antigen will gain entry into
the exogenous MHC-II mediated antigen presentation pathway. And so, although
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plasmid-harboring somatic muscles cells are able to act as provisional APCs and present
the antigen to the immune system on the context of MHC-I complexes, there most
important role in priming the immune system relies on acting as low-level, antigenproducing “factories” secreting antigen to the extracellular compartment for long periods
post-transfection. And so, like the viral proteins produced by a replicating virus, vaccine
plasmid product may gain access to both pathways simultaneously (endogenous/MHC-I
and exogenous/MHC-II), affecting its presentability to the immune system. DNA
vaccination is able then to induce a strong both humoral and cellular immune response
against the plasmid-encoded antigen. [159,162]
Although most of the cells transfected are muscle cells, these can only present the
antigen to immune cells via MHC-I complex, as they are not actually professional antigen
presenting cells and so lack the capacity to present antigens via MHC-II complexes and
prime CD4+ helper cells, or transport these antigens to lymph nodes or to secrete the costimulatory molecules (e.g., GM-CSF, IFN-γ, IL-2, IL-12) necessary to activate an
effective CD8+ T cell immune response and avoid anergy. This is why, despite their
considerably lower numbers at the injection site professional APCs, such as DCs are held
as the key inducers of immunity in genetic immunization, distinguishing them as the
immunological bridge between somatic cells (such as muscle cells or keratinocytes) and
naïve T lymphocytes cells by the trafficking of antigen between the site of delivery to
secondary lymphoid organs. [159,162]
DCs prime the immune system to vaccine antigen in at least three distinct ways:
(1) MHC-I restricted presentation by the small population of directly transfected tissue-
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resident professional APCs that uptake the DNA plasmid at the actual vaccination site.
[159,163] Upon exposure with the plasmid DNA antigen these cells become highly
activated, express, process, and present the antigen and then migrate to draining lymph
nodes where they interact with naive T cells and are capable of inducing humoral and
cell-mediated immune responses. [159] The significance of this extremely small number
of resident DCs in genetic immunization has been demonstrated in transplantation studies
that show the induction of a CTL response is restricted to the MHC haplotype of bone
marrow-derived APCs and not to the haplotype of transfected somatic cells, following IM
and gene gun administration of plasmid DNA. [162,164] (2) MHC-II restricted
presentation to T cells of antigen captured from transfected muscle cells. This mechanism
of inducing immunity relies on the phagocytic ability of DCs to capture secreted forms of
the vaccine antigen expressed by plasmid-transfected muscle cells, which as stated before
act as antigen “factories”. These are processed in the exogenous pathway and loaded onto
MHC class II molecules. When these DCs receive the proper maturation signal, they upregulate co-stimulatory molecules and then migrate to and communicate with antigenspecific CD4+ helper T cells, which are then induced to secrete Th2 cytokines. Usually,
antibody responses occur only when antigen is secreted from cells. Although antigen
secretion may help to augment the development of a strong humoral response, it has not
been shown to induce CTLs and, therefore, cannot act independently from the other two
mechanisms of immune system priming. [159] (3) MHC-I restricted “cross”-presentation
of captured and processed exogenous vaccine antigen captured from transfected apoptotic
muscle cells. Given the right conditions, including most likely the presence of a “danger”
signal or a proinflammatory environment (such as the ones promoted by the physical
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microinjury that results from the vaccination act or by the immunostimulatory sequences
present in the vaccine plasmid itself, in the case of Oncept®), a proportion of the
transfected somatic muscles cells will enter apoptosis leaving behind (among other
cellular debri) MHC-I/vaccine antigen cell membrane sections. APCs, under that context,
may capture and phagocytize these antigen–loaded MHC-I apoptotic sections. This way,
exogenous plasmid-encoded antigen, which would normally be handled by the exogenous
pathway and presented to helper T cells via MHC-II complexes, is able to enter the
endogenous pathway instead and be cross-presented to cytotoxic CD8+ T cells in the
context of MHC-I molecules. Following migration to lymph nodes, cross-presenting DCs
can expand (cross-prime) or delete (cross-tolerate) antigen-specific naïve CD8+ T cells in
the periphery, depending on the environment in which the DC captured the antigen (i.e.,
the presence or not of “danger” signals). But the effective cross-priming of naive T cells
to exogenous antigen requires also the active involvement of CD4+ helper T cells [165];
and so it is most likely that all of these mechanisms are necessary in genetic vaccination
and must act in conjunction in order to evoke a potent humoral and cell mediated
response.
But within the periphery, immature DCs exist in a highly phagocytic state, which
although helps in their uptake of secreted or apoptotic antigen, it is also characterized by
the low-level expression of MHC class I, MHC class II, and costimulatory molecules,
rendering them poor initiators of immune responses. These immune cells in order to carry
over their crucial role need to receive the proper maturation signal. DC maturation can be
induced also by the method of plasmid delivery and by the immunostimulatory qualities
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of plasmid DNA. The act of injection during the administration of DNA plasmids are
forms of physical microinjury that result in local irritation, which has been shown to
stimulate the recruitment of non-transfected DCs to the injection site, as well as the
migration of transfected DCs from there to the draining lymph nodes [166]. In this way,
the physical stress associated with invasive DNA delivery acts as a type of
immunological adjuvant. The plasmid construct of this DNA tyrosinase vaccine possess
itself adjuvant qualities that are determined by the presence of immunostimulatory
sequences within the DNA vector backbone. In there, repeated immunostimulatory
unmethylated CpG motifs act to initiate the innate immune response, by promoting the
secretion of pro-inflammatory cytokine mediators from macrophages (IFN-α, IL-12) and
natural killer cells (IFN-γ, IL-18), thereby promoting the maturation of DCs (upregulating the expression of MHC-II molecules), as well as promoting the differentiation
of naive T cells to Th1 cells [159]. Once they receive the proper maturation signal
vaccine antigen loaded DCs up-regulate costimulatory molecules and then migrate to
regional lymphoid organs, where their numbers consequently increase because of influx
or expansion from precursors [166] and communicate with antigen-specific naïve helper
T cells, which are then induced them to secrete both Th1 and Th2 cytokines [159,162]
promoting the initiation of humoral and cellular vaccine antigen specific immune
responses. Furthermore, communication with CD4 cells induces the ability of the DCs to
activate naïve CD8+ cells via CD4+ signaling [167] and also induces the establishment of
vaccine antigen specific memory CD4+ and CD8+ T cells that are capable of long-life
existence.
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7. Evaluating response to anticancer immunotherapy: looking at more than just
reductions in tumor size

Unlike radiotherapy and chemotherapy, wherein tumor regression is the standard
for determining efficacy of treatment, immunotherapy has to be evaluated by the
examination of several immunological aspects within patients, and not only clinical
response. [168,169] That is why it is critically important to implement in vitro
immunological assays that correlate with clinical outcome, for their use as monitoring
tools in cancer patients undergoing immunotherapy as surrogate markers of vaccine
efficacy and for helping in the optimization of these immunotherapeutic strategies before
jumping to large scale randomized clinical trials. [168] In order to get a complete picture
of this immune response mounted by the vaccine stimulation, both the humoral as well as
the cellular arms of the immune system should be simultaneously evaluated. But if indeed
the titer of circulating antigen-specific antibodies can serve directly as an indicator of the
efficacy of a vaccination protocol in inducing a humoral response and antigen-specific
ELISA can serve as a validate method to evaluate it, choosing the adequate method to
evaluate the other arm of immunity, the cellular response is a little more complicated.
And furthermore, the past notion that the antibody response is more important than the
cellular response in the context of anticancer vaccination has not only been challenged
but it has actually been proposed that the cellular arm is the one that most importantly
mediates tumor regression through this treatment approach. [170,171] In this context,
because tumor antigen-specific antitumor immunity depends on CD8+ cytotoxic and
CD4+ helper T-cells assays that monitor their stimulation and function are of particular
importance. In order to do accomplish this there is a plethora of in vitro antigen-specific
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assays that can be used, all with advantages and disadvantages. Among the assays that
have been described in the literature them lymphoproliferation assays, detection of
secreted cytokines by ELISA or ELISPOT, quantification of cytotoxic T-cell precursors
by limiting dilution analysis, flowcytometry, and real time PCR are the most important.
But some of these assays like the lymphoproliferation assays are only used as a screen
tool to indicate whether any immune response to the vaccination has been induced before
performing more informative assays. Other assays like cytokine detection ELISAs, which
detects the presence of antigen-specific activated T-cells by measuring their bulk
cytokine production after encountering the specific antigen during incubation, although
being able of providing function information, fail in giving quantifying information about
individual antigen-specific T-cells, and so has consequently been replaced by measures of
individual cell cytokine release. ELISPOT is one of these measures, and so one of the
best choices for quantifying T-cell responses in clinical trials. In fact it has been used in
the past to evaluate cellular immune response in dogs after tyrosinase DNA vaccination.
Although it does succeed detecting and enumerating individual cytokine producing
antigen-specific activated T-cells, it suffers the cumbersome that it requires considerable
expertise and rigorous attention to performance, especially in the counting phase. This
human factor certainly interferes with reproducibility. Quantifying citotoxic T-cell
precursors by limiting dilution analysis is an older type of assay that suffers the same
limitations of being both labor intensive and extremely operator dependant. [172] The
detection of cytokines secreted by antigen-specific activated T-cells using flowcytometry
is another technique that has considerable utility and sensitivity, which in fact was tried
in this study, but without providing reliable and reproducible results. Real time PCR,
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which works by evidencing and most of all relatively quantifying the cytokine response
of specific-antigen stimulated T-cells by measuring the levels of gene transcripts in
samples of mRNA, was the methodology chosen in this study to measure the cellular
immune response mounted by the anticancer vaccination stimulation. This technique has
many advantages, among them the biggest is its high flexibility, since it allows the study
the genes of interest (virtually any gene for whom the sequence is known) in a broad
range of samples with minimal amounts of material. Another crucial advantage is its very
high sensitivity, being able to detect transcripts with very few amounts of product. This
ability has been greatly improved by the relatively recent development of mRNA preamplification techniques, which allow for the quantitative analysis of genes with very
low product yield while maintaining their proportional expression levels. [173,174] The
cytokine chose to reflect anti-tumor specific T-cell activation in this case was INFg,
which has the advantage over IL-2, IL-4 and IL-12, that is not secreted by unestimulated
PBMC. [174] This particular approach had been previously reported with success in the
literature in studies involving anticancer vaccination for, among other cancers,
melanomas in humans and mouse models. [173,174] And it has been previously reported
with an immunotherapeutic approach using IL-12 DNA plasmid constructs in horses with
melanoma. [128]
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Appendix of Tables and Figures
Table 2.1. Advantages and disadvantages of the different types of anti-cancer vaccines (table modified
from: Wolchok JD, Livingston PO. Vaccines for melanoma: translating basic immunology into new
therapies. Lancet Oncol. 2001 Apr;2(4):205-11).

Table 2.1
Types of anti-melanoma vaccines

Type of vaccine

Advantages

Disadvantages

Allogeneic cellular

Simple to prepare
Presents broad spectrum of potential
antigens

Presents irrelevant 'allo' antigens
Difficult to precisely characterise
components

Currently in phase II clinical trials

Requires adjuvant
Requires laborious individual vaccine
production

Autologous
cellular

Presents patient-specific unique antigens
Presents numerous antigens

Heat shock
protein
Peptide
DNA

Presents patient-specific unique antigens

Requires adjuvant
Requires laborious individual vaccine
production

Presents numerous antigens

Unproven immunogenicity

Simple to prepare

Requires adjuvant

Safety established in early trials

Only presents single epitope HLA-restricted

Simple to prepare

Little clinical data to date

Numerous epitopes presented
Immunostimulatory sequences in vector
Recombinant
virus

Inherently immunogenic

Neutralising immunity to vector

Presents numerous epitopes
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Figure 2.1. Figure showing comparative pictures of one of the melanoma-bearing gray horses in our
clinical trial. (A) Younger picture showing the horse’s original coat colors. On the background of the
picture appears her dam, already gray and also with history of melanomas. (B) The same horse by the time
of enrolment in the clinical trial, completely gray by that point and with melanomas at multiple sites.
(Picture on “A” courtesy of Dr. Karla Clark).
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Figure 2.2. Classical presentations and locations of equine melanomas (A) Subcutaneous melanoma
located in the temporal region. (B) Invasive melanoma associated with the parotid salivary gland. (C)
Dermal melanoma located at the commissure of the lip. (D) Multiple dermal melanomas on the penis and
prepuce. (E) Multiple confluent peri-anal melanomas (dermal melanomatosis), note areas of marked
depigmentation within the tumors (arrow). (F) Large dermal melanoma at the ventral surface of the base of
the tail, note further complication by ulceration and infection.
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Figure 2.3. Image showing splenic parenchyma severely compromised by diffuse metastatic lesions. This
image was obtained at necropsy of a gray horse that presented with a large necrotic dermal melanoma at the
base of the tail (Courtesy of Dr. Karla Clark).
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Figure 2.4. Illustration of intra-tumoral chemotherapy and hyperthermia administration. (A) Large perianal
melanoma that is being treated with intra-tumoral injections of cisplatin. Needles are pre-placed evenly
throughout tumor. (B) The tumor was then treated with local hyperthermia using a prototype microwave
therapy unit (Thermofield® System, Parmenides, Inc.). Massive tumor shrinkage was achieved clinically
in this patient.
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Figure 2.5. Melanin synthetic pathway and the involvement of melanogenic enzymes. Initial melanin
synthesis is catalyzed by tyrosinase and is then divided into eumelanogenesis or pheomelanogenesis. The
other melanogenic enzymes, L-3,4-dihydroxyphenylalanine (DOPA) chrome tautomerase (DCT) and
tyrosinase-related protein 1 (TYRP1), are involved in eumelanogenesis (Source: Ando H, Kondoh H,
Ichihashi M, et al. Approaches to identify inhibitors of melanin biosynthesis via the quality control of
tyrosinase. J Invest Dermatol. 2007 Apr;127(4):751-61)

Figure 2.6. Plasmid map of pING plasmid used for generation of human tyrosinase DNA vaccine given to
nine dogs with advanced malignant melanoma. (source: Bergman PJ, McKnight J, Novosad A, et al. Longterm survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human
tyrosinase: a phase I trial. Clin Cancer Res. 2003 Apr;9(4):1284-90).
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Chapter 3 : Evaluation of Needle-free Injection Devices for
Intramuscular Vaccination in Horses
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CHAPTER III
Brief explanatory statement:
This chapter is a slightly revised version of a manuscript that has been published in the
“Journal of Equine Veterinary Science” on December 2011, documenting the validation
of a needle free injector as a proper tool to efficiently deliver a plasmid DNA construct
vaccine to its site of action (muscle tissue) in the horse. It also included the identification
of the pectoral muscles as the most adequate site for this plasmid DNA vaccine in this
species.
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Abstract
Needle-free injection devices have been approved for the delivery of biologics
within herently low immunogenicity, such as plasmid DNA vaccines; however, no
studies have described their use in equine patients. This article compares the use of two
such devices (VitaJet-3 and Biojector2000) at typical vaccination sites in a cohort of six
horses. After identifying the optimal device and vaccination site, a second cohort of five
horses was used to document the biologic activity of a DNA plasmid vector delivered
with the selected injector. Injector characteristics, including the amount of intramuscular
drug deposition, residual skin dose, and pain responses, were evaluated following
vaccination, with colored saline in the pectoral muscles and cervical region in six horses.
The optimal device was then selected and used for intramuscular vaccination with the
pING/tyrosinase plasmid vector in a group of five horses. Biological activity was
measured through antibody response to the protein encoded by the plasmid on days 0, 14,
28, 42, and 56postvaccination. Optimal intramuscular dose delivery was obtained in the
pectoral muscle site using the VitaJet-3. No significant pain responses were noted.
Dependent edema was seen at vaccination sites 24 hours after therapy. Antibody
responses to the protein encoded by the DNA plasmid vector significantly increased after
vaccinations in all horses. The VitaJet-3 is easy to use and is effective for delivering
intramuscular vaccinations with DNA plasmid vectors in horses. This device allows for
vaccination with vectors that exhibit low immunogenicity and/or that require targeted
delivery to specific tissue planes.
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Introduction

Transdermal needle-free injection devices have been proposed as an alternative to
traditional needle injections. The benefits of these devices include the ability to deliver to
selected tissue planes both high- and low-dose injectates with minimal pain. Furthermore,
the immune response generated after vaccination with needle-free devices seems to be
superior to that elicited from traditional intramuscular injections [1]. Other potential
benefits include reduced vertical transmission of blood-borne diseases, elimination of
inadvertent needle sticks, ease of administration, reduced medical waste, and improved
ability to vaccinate aggressive animals.
Needle-free injection devices work by delivering liquid medications (including
vaccines) through a nozzle orifice under high pressure, thus generating a narrow stream
that penetrates the skin [1]. The distribution of medication after it penetrates the skin is
significantly wider than that obtained with traditional needle devices, thus allowing for a
larger contact volume between vaccine and immune cells [1]. The specifications of
different jet injectors vary by nozzle diameter, injection pressure, velocity, and stand-off
distance; it is these factors, in conjunction with the skin characteristics that dictate the
distribution of drug in tissue [2].
The use of these devices has been described in a variety of species, including
human and nonhuman primates, dogs, cats, pigs, sheep, and other livestock [3-8].
Controlled clinical studies in humans suggest a somewhat higher rate of adverse local
reactions compared with traditional needle devices, with pain generally less than, or
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similar to, needle-syringe injections [8]. However, studies regarding sheep, dogs, and
cats, have demonstrated both ease of administration and a low rate of adverse local
reactions [4-8].Furthermore, studies related to companion animals have demonstrated that
these devices have a greater ability to deliver to selected tissue planes, and in some cases,
to elicit a superior immunologic response [1,9]; these are important factors for biologics
with relatively low immunogenicity such as plasmid DNA vaccines [10]. In fact, the only
commercially available plasmid DNA vaccine for companion animals is licensed for
administration using a needle-free injector [11].
Despite these perceived benefits, no studies have specifically assessed the use of
needle-free injectors in horses. These devices will become important as novel, and in
some cases poorly immunogenic, vaccine therapies are developed for the horse. Thus, the
primary objective of this study was to evaluate two needle-free devices (which had
previously been validated in the dog) for intramuscular drug delivery in the horse.
Variables that were assessed included vaccination site, amount of intramuscular drug
deposition, local site reaction, and pain response during vaccination. As a secondary
objective, the optimal device was then chosen for use in a field study to confirm its
ability to generate appropriate immune responses in horses vaccinated with the DNA
plasmid vector pING/tyrosinase, the transcriptional activity of which requires specific
delivery and uptake by muscle cells [10].
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Materials and Methods
Institutional Animal Care and Use Committees, at both the University of
Tennessee and at Merial Limited, reviewed and approved all husbandry practices and
animal procedures used in this study.
Animals
A total of 11healthy adult horses (age: 8 to 12 years) were used in this study.
Local site reactions and pain response were evaluated in all the horses. The horses were
divided into two groups. The first group included six Thoroughbreds who were used to
evaluate the characteristics of the two vaccination devices. These privately owned horses
were donated to the University of Tennessee Veterinary Teaching Hospital for humane
euthanasia immediately following vaccination. The second group of five adult Quarter
horses belonged to the University of Tennessee College of Veterinary Medicine teaching
herd. These horses were used to determine both immunologic response following
vaccination and to evaluate local reactions after repeat vaccination.
Injection Devices

Two injection devices were evaluated: the VitaJet-3(VitaJet-3 is a registered
property of Bioject, Inc) spring-activated device and the Biojector 2000 (BioJector 2000
is a registered property of Bioject, Inc) jet delivery device. TheVitaJet-3 is a springactivated injection device designed to deliver medication intradermally, subcutaneously,
or intramuscularly (IM). The device consists of the injector and disposable syringe that
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can deliver between 0.2 and 0.5mL of liquid. The B2000 is a CO2-powered, needle-free
jet injection device designed to deliver medication or vaccine either subcutaneously, IM,
or intradermally. It consists of an injector, disposable CO2 cartridges, and a disposable
syringe that can deliver between 0.2 and 1.0 mL of liquid. Both devices function using a
single-injection pressure of130 psi for the VitaJet-3 and 150 psi for the B2000 Nozzle
size and stand-off distance determine the depth of penetration; in this study, both the
devices used a 0.007-inchnozzle diameter and 1-mm stand-off distance designed for
optimal intramuscular injections.
Comparison of Injection Devices
The two injection devices were compared with respect to the amount of
intramuscular drug deposition, residual skin dose, effect of hair clipping, and local site
reaction. To determine the amount of intramuscular drug delivered by each device, two
injection sites were used in both the anterior superficial pectoral and lateral cervical
regions of six horses in the first group (Figure 3.1). The sites to be injected were
separated by a minimum of 5 cm, with one of the two sites clipped free of hair for each
region. Injectate was composed of 0.9% sodium chloride, with tissue dye added for
localization. For the VitaJet-3, 0.5 mL of injectate was administered into the haired and
non-haired skin in the pectoral and cervical regions. For the B2000, 1.0 mL of injectate
was given at similar locations. Residual skin injectate was documented schematically,
and was measured by determining the area of the circle created on blotting paper held to
the region. The horses were euthanized and the tissues were carefully dissected to
visualize dye penetration. The amount of intramuscular drug deposition was determined
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subjectively by estimating the relative quantity of tissue dye deposited within the
intramuscular plane and reporting it semi-quantitatively as either <33%, 33% to 66%, or
>66% of the total visible dose. Observations including local site reaction, pain response,
and the site/amount of injectate deposition were documented. The preferred injection
device and anatomic site were selected on the basis of the analysis of these observations
and used in the subsequent vaccine study.
Vaccination with Ping/Tyrosinase DNA Plasmid
The DNA plasmid pING/tyrosinase (Oncept® Merial Limited, Athens, GA, USA)
is a United States Department of Agriculture-licensed vaccine for immunotherapy of
canine melanoma. Activity of this vaccine requires specific delivery and uptake of the
plasmid by muscle cells [10]. For evaluating the ability of needle-free injectors to
effectively deliver this vaccine in horses, test vaccinations using the VitaJet-3 were given
into a clipped location in the anterior superficial pectoral muscles of five horses.
Vaccinate was composed of0.4mL (100 ug) of xenogenic DNA plasmid coding for
human tyrosinase (Oncept®, Lot No. 30105). Each horse received a series of four
biweekly vaccinations, alternating between right and left pectoral muscles for each
vaccine. Initial observations including local site reaction, pain response, and residual skin
injectate were documented in all horses. Local site reactions were assessed by visual
observation of any changes at the injection site post-vaccination. Pain responses were
evaluated subjectively using a previously described pain scoring system and through
documentation of any observed behavioral changes [12]. Local site reaction and pain
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response (if any) were evaluated again in each of the five horses, 24 and 48 hours postvaccination.
Immunologic response following vaccination was measured by documenting
specific serum antibody response to the protein encoded by the plasmid vector (human
tyrosinase).Therefore, serum samples were collected on day 0,14, 28, 42, and on day 56,
2 weeks following the final vaccination. Antibody responses were measured using the
standard enzyme-linked immunosorbant assay technique, similar to those described
previously [4,13]. Briefly, full length human tyrosinase protein (0.05 mg) was applied to
each well of a 96-well microtiter plate. Plates were washed and patient serum was applied
in triplicate using dilutions from 1:20 to 1:540. After 1-hour incubation, plates were
washed again, and a secondary goat anti-horse IgG, labeled with horseradish peroxidase,
a reporter molecule, was applied for 1 hour. A final wash was then performed, and the
plates were developed by adding peroxidase substrate. Antibody responses were
determined by measuring the absorbance of each well at a wavelength of 450 nm using
the ELx800 Microplate reader instrument (BioTek Instruments, Limited, Winooski, VT,
USA).
Statistical Analysis
The effects of hair clipping, vaccination site, and vaccination device on residual
skin injectate and amount of intramuscular drug deposition were evaluated using the
paired Student t-test to identify significance differences (P <.05) [14]. Semi-quantitative
values for intramuscular drug deposition were given categorical “scores” of 1, 2, and
3(corresponding to <33%, 33% to 66%, >66%, respectively) for analysis, with higher
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scores suggesting increased total intramuscular drug deposition. Residual skin injectate
was measured in surface area with values analyzed directly. All other device
characteristics (local site reaction, visible pain response) are reported individually, as
noted. Mean baseline antibody responses were used to determine a positivity threshold,
defined as >2 standard deviations above the mean baseline value, above which
immunologic responses were considered significantly positive, as reported previously
[15]. Immunologic responses were further evaluated to determine the significance of any
increases following vaccination. Data were first evaluated for normality using the
Shapiro-Wilk normality test [14]. The data did not follow a normal distribution;
therefore, the nonparametric sign test of matched pairs was used to compare the
immunoreactivity values before and after vaccination [14]. All statistical analyses were
performed using STATA 11.1 Data Analysis and Statistical Software (StataCorp LP,
College Station, TX).
Results
Comparison of Injection Devices

Device characteristics for the VitaJet-3 and the B2000 were evaluated at both
cervical and pectoral injection sites in the first group of six horses. When used in the
pectoral region, both devices deposited the majority of the visible injectate IM following
each injection. The median intramuscular drug deposition for the VitaJet-3 was 3 (range
= 1 to 3, x̄ = 2.7, σ = 0.6), whereas the median for the B2000was 2 (range = 1 to 3, x̄ =
2.3, 2, σ = 0.8) (Fig. 3.2). Although there was a visible trend toward increasing
intramuscular drug deposition using the VitaJet-3 in the pectoral location, no significant
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difference was noted between the devices using the categorical scores (P = .053). Tissue
dissection of the cervical injection sites, however, showed relatively poor intramuscular
drug deposition with either device. Visibly, the majority of injectate appeared to be
localized to the subcutaneous region and between fascial planes for all injections (Fig.
3.2). For the cervical site, median intramuscular drug deposition for the VitaJet-3 was 2.0
(range = 1 to 2, x̄ = 1.5, σ = 0.5), whereas for the B2000 it was 1 (range = 1 to 2, x̄ =
1.4, σ= 0.5). No statistical difference was found in the amount of intramuscular
deposition for the two devices in the cervical region (P = .44). Comparing results from
both regions, we found that injection over the pectoral muscles resulted in significantly
more intramuscular deposition of the drug than did injections made in the cervical region,
for either device (P = .001).The effect of hair clipping on drug deposition and residual
skin injectate was also evaluated. Intramuscular drug deposition at clipped pectoral site
received a median score of 3 (x̄ = 2.8, σ = 0.4) compared with 2 ( x̄ = 2.2, σ= 0.9) for
non-clipped pectoral sites. No significant difference was noted in the depth or tissue
localization of injectate at injection sites that had been either clipped or non-clipped prior
to injection (P = .14). Residual skin amounts in both clipped and non-clipped pectoral
injection sites, quantified by the surface area, varied between 0 and 49 mm2 for both
devices, with a median values of 6.5mm2 (σ= 19) for the VitaJet-3 and23mm2 (σ= 20) for
the B2000. No significant difference was found between residual injectate found on the
skin surface for either device at either clipped or at non-clipped locations (P = .3). Similar
results were found for the effects of hair clipping at cervical injection sites. Finally, no
evidence of local site reactions or obvious pain responses (score) was observed in this
first group, as determined by physical examination, behavioral, or postural changes. On

74

the basis of these results, vaccination in the pectoral muscles using theVitaJet-3 was
selected for evaluation in a field trial using the plasmid vector pING/tyrosinase.
Vaccination with the pING/Tyrosinase Plasmid and Immune Response
To evaluate the use of the VitaJet-3 in a small clinical field trial, the device was
used to deliver a DNA plasmid vaccine to five horses. These horses were evaluated for
acute pain responses, local site reactions, and immunologic response to the protein
encoded by the DNA plasmid. No clear pain responses were seen in any of the horses;
however, two horses appeared to be startled by the activation of the injection device.
Similarly, no discernible physical changes (local site reactions) were observed
immediately following vaccination. The delayed effects of vaccination and the effects of
multiple vaccinations were evaluated at 24 and 48 hours post-vaccination. At 24 hours
post-vaccination, all the horses exhibited mild dependent edema in the pectoral muscles
immediately ventral to the vaccination site. Evaluation at 48 hours post-vaccination noted
near-resolution in the amount of dependent edema in all the horses, with no other longterm local effects observed. Human tyrosinase-specific antibody titers for the five horses
are shown in Figure 3.3. The immunoreactivity threshold was set at two standard
deviations above the mean baseline value ( x̄ = 0.13, σ = 0.02) at an Optical Density450=
0.168. Positive immunoreactivity values were noted in all horses following completion of
the vaccination protocol. As expected, these titers varied between patients but generally
increased throughout the protocol. Overall, a significant (P =.03) increase was seen in
humoral response that ranged from two- to threefold higher in the post-vaccination sera at
day 56 compared with the pre-vaccination sera at baseline on day 0.
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Discussion
Here we have demonstrated that both pneumatic and spring-actuated needle-free
injection devices can be used to successfully deposit intramuscular medications in the
pectoral region of horses; however, the spring-actuated device (VitaJet-3) was found to
be superior. Further, although both cervical and pectoral locations are commonly used for
“needle-based” intramuscular injections, the pectoral location was preferred for the
needle-free devices, based on the improved intramuscular deposition of injectate.
Cervical locations in the horse are characterized by fairly thin muscle planes separated by
fascial planes and connective tissue [16]. These characteristics, along with the nozzle
diameter and injection pressure, led to a large proportion of the dose being deposited
within the fascial planes for cervical injections rather than in the desired intramuscular
area. In contrast, pectoral locations have fairly deep muscle compartments and minimal
connective tissue, ideally suited for the injection devices used herein. These tissue
characteristics compare favorably to those seen in the dog, where the deep muscle
compartment of the upper medial thigh was found to be the preferred location for
intramuscular needle-free injections [9]. Evaluation for local site reactions and pain
response was performed in all the horses. No significant acute local reactions or pain
responses were noted. Localized ventral edema occurred in most horses 24 hours after
vaccination, which resolved over the following 24 hours. The frequency and magnitude
of these local site reactions were, in the authors’ opinion, comparable with those expected
from intramuscular needle injections. Subjectively, pain responses appeared significantly
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less than with traditional needle vaccinations. A larger, comparative study would be
required to definitively evaluate these local site reactions.
Detectable immune responses to the vaccine used herein require the successful
intramuscular deposition of vaccinate, uptake of the plasmid by muscle cells, along with
expression and presentation of the plasmid-encoded protein [10]. Previous work had
already defined the stability of vaccines (both DNA-based vaccine and traditional
vaccines) delivered through needle-free devices and their use for intramuscular injection
[1,2,8,9]. Humoral responses were, therefore, determined as a further measure to validate
the use of needle-free injection in horses. All horses developed two- to threefold
tyrosinase-specific antibody increases, which were comparable in timing and magnitude
to those seen in canine patients vaccinated using the same plasmid [4,13]. These values
are reasonable given the low immunogenicity of the DNA plasmid vector [4,13].
Although other studies have suggested that needle-free devices elicit a superior immune
response [1,9], this study was not designed to evaluate differences between traditional
and needle-free devices in horses. Herein, we demonstrate that use of the VitaJet-3, along
with 0.007-inch nozzles, seems to be safe for intramuscular drug delivery of aqueous
solutions and may avoid some of the risks associated with traditional needle devices such
as clostridial myositis and needle-stick accidents. [17] Further, detectable immune
responses are developed to weakly immunogenic vectors such as DNA plasmid vectors,
when using this device.
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Appendix of Tables and Figures

Figure 3.1..Demonstration of the correct way of performing an intramuscular (IM) injection in the pectoral
muscles of a horse using the VitaJet-3 needle-free injection device. Note perpendicular angle to the muscle.
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Figure 3.2..Results from IM injections (A) Results of injections into the pectoral muscles using the B2000
(left) and VitaJet-3 (right) needle-free injections; note the lack of discernible acute reaction and residual
skin injectate. Arrows denote unclipped injection sites. (B) Distribution of injectate (blue) into the pectoral
muscles using the VitaJet-3; note the majority of dose is deposited intramuscularly. (C) Distribution of
injectate (blue) into cervical muscles using the VitaJet-3; note the majority of dose is deposited
subcutaneously
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Figure 3.3. Specific IgG humoral immune responses to human tyrosinase vaccination with the VitaJet-3
needle-free injection device in horses. Positivity threshold, which was set at an OD 450= 0.168 corresponding
to two times the standard deviations above the baseline mean of the group, is denoted by a dashed line.
Arrows represent actual vaccination time points. A significant (P =0.03) increase in humoral response,
ranging from a two- to threefold increase, was observed when comparing post-vaccination sera at day 56 with
the pre-vaccination sera at baseline on day 0.
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Chapter 4 : Evaluation of Tyrosinase Expression in Canine
and Equine Melanocytic Tumors
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CHAPTER IV
Brief explanatory statement:
This chapter is a slightly revised version of a manuscript that has been published in the
“American Journal of Veterinary Research” on February 2012. It documents the
identification of the substantial overexpression of tyrosinase mRNA in equine melanoma
tissue in comparison to equine normal skin tissue by Real-Time PCR. As tyrosinase is the
immune-target of the melanoma vaccine tested in these studies this particular project
provided a “proof of target” for this immunotherapeutic strategy in this species.
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Abstract
The main objective of the present study was to determine the tissue-restricted
expression pattern of tyrosinase mRNA in canine and equine melanocytic tumors and
relative tyrosinase and major histocompatibility complex (MHC) I mRNA expression in
variants of melanocytic tumors. For this purpose 39 canine and 8 equine tumor samples
and 10 canine and 6 equine normal tissue samples were selected from the anatomical
pathology archive of the University Of Tennessee College Of Veterinary Medicine. RNA
was isolated from formalin-fixed paraffin-embedded tissues. Real-time PCR assays were
designed to amplify canine and equine tyrosinase, S18 ribosomal RNA, and major
histocompatibility complex I transcripts. Relative expression was determined by use of
S18 as a reference gene and comparison with pigmented and non-pigmented normal
tissues. High tyrosinase expression was found in all melanocytic tumors, compared with
normal tissues, and expression had no correlation with presence or absence of tumor
pigmentation. No significant difference in tyrosinase expression was found among
histologic variants of melanocytic tumors. No correlation was found between MHC I and
tyrosinase expression or tissue histologic classification. In the present study, the methods
used were highly sensitive and specific for detection of tyrosinase expression in equine
and canine tumors, and overexpression of this transcript in melanomas was detected. This
suggested that a DNA vaccine developed for use in dogs with melanoma that targets
tyrosinase may be considered for use in other affected species, such as horses.
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Introduction

Tyrosinase is a copper-containing type I membrane glycoprotein essential for
melanin

synthesis.

Tyrosinase

catalyzes

the

hydroxylation

of

tyrosine

to

dihydroxyphenylalanine, which is considered the rate-limiting step in melanin production
[1]. In humans, tyrosinase is expressed in epidermal melanocytes as well as the
pigmented epithelia of the retina, iris, and ciliary body of the eye [2,3]. This expression
appears to be tightly controlled both spatially and temporally through a variety of cisacting and trans-acting elements [4]. In brief, tyrosinase expression is up-regulated in
developing melanocytes and down-regulated in mature and quiescent melanocytes [1,4].
In contrast, in neoplastic tissues, tyrosinase expression appears constitutively increased in
all malignant melanocytic tumors [4,5]. Because of the tight temporal and spatial
regulation in normal tissues (and the high expression in tumor tissues), tyrosinase has
proven to be a useful target for immunotherapeutic approaches in humans with
melanocytic tumors [6].
Much of the information regarding tyrosinase expression has been derived from
human and rodent cell lines and histologic samples [1–5]. Although a commercially
available xenogenic tyrosinase vaccine for the treatment of dogs with melanoma has had
encouraging results, minimal published information exists on the tissue-specific
expression of canine or equine tyrosinase [7,8]. Gene and protein expression studies have
identified detectable expression of tyrosinase in canine and equine tissues, respectively
[9,10]. A genetic study has identified mutations associated with development of
melanocytic tumors in gray horses; these mutations are thought to result in up-regulation
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of genes such as tyrosinase [11]. However, no large-scale or comparative tyrosinase gene
expression has been described in either species. Further information on the expression of
canine tyrosinase may be useful to understand the role of targeted immunotherapy in
dogs with melanocytic tumors. Furthermore, data on the expression of tyrosinase in
equine melanocytic tumors may support the use of this immunologic modality in a
different species.
The MHC I gene complex is a component of the antigen-processing machinery
that is commonly dysregulatedin tumor tissues [12]. Down-regulation of this gene may
result in the development of resistance to targeted immunotherapies [12,13]. Correlations
between MHC-I expression and tissue type may thus prove useful in further
understanding the response to treatment in patients treated with tyrosinase-targeted
immunotherapy. The primary objective of the study reported here was to determine the
relative expression of tyrosinase mRNA in a series of canine and equine melanocytic
tumors. The secondary objective was to determine the relative expression of antigen
presentation gene MHC-I mRNA in this series of tissue samples.
Materials and Methods
Tumor samples

Canine and equine FFPE tumor samples were obtained from the University of
Tennessee College of Veterinary Medicine pathology database. Samples were identified
through a medical record search by use of the keywords melanoma, amelanotic
melanoma, and melanomatosis. With the use of these search terms, 22 equine cases and
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765 canine cases were identified between January 1, 2000, and December17, 2007; 70
canine and 8 equine cases were selected for further review on the basis of the availability
of adequate FFPE tissue blocks. From these tissue blocks, individual cases were then
reviewed for tumor histologic classification and complete medical record with diagnosis,
treatment, and, in some cases, follow-up information.
Canine tumor histologic examination included sampling of both oral and non-oral
melanomas. Non-oral locations included cutaneous benign melanomas, cutaneous
malignant melanomas, and digital melanomas. Equine tumor histologic examination
included benign cutaneous melanomas, malignant cutaneous melanomas, and
melanomatosis (disseminated melanomas). Slides from all 78 tumors were reviewed by a
board-certified pathologist (SJN). Ultimately, 39 canine and 8equine tumors remained
that contained adequate and appropriate tissue for further analysis.
Control samples
Control tissue samples were isolated from animals necropsied at the University Of
Tennessee College Of Veterinary Medicine with no evidence of melanocytic tumors.
Canine control tissues included pigmented and non-pigmented normal cutaneous and oral
tissue. In addition, 2 anaplastic sarcomas (melan-A and S100 negative via
immunohistochemical analyses) were included as tumor control tissues. Equine control
tissues included pigmented and non-pigmented cutaneous tissue from both gray and nongray horses. These samples were FFPE by use of standard procedures. Histologic
classification was confirmed by a pathologist (SJN).
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RNA isolation
The RNA was isolated from FFPE tissues by use of a kit (SurePrep RNA Isolation
kit, Fisher Scientific, Waltham, MA, USA) in accordance with the manufacturer’s
instructions. Paraffin-embedded tumor sample blocks were selected by a pathologist
(SJN). Five 20 μm sections were then cut from each tissue block by use of a microtome.
Blocks and sections were manipulated to include only tumor tissues and carefully avoid
overlying normal cutaneous tissues. Sections were transferred to a microcentrifuge tube
and deparaffined with xylene. Tissue was then washed with ethanol and air-dried.
Cellular lysates were prepared by use of digestion buffer with proteinase K. Binding
solution and ethanol were added to the lysates. Lysates were applied to RNA-binding
columns, washed, and eluted. Final RNA quality and concentrations were determined by
evaluating absorbance at optical densities of 260 and280 nm. Although concentrations
varied widely, typical values were > 300 μg/mL. Following RNA quantification, samples
were stored at –80°C until analysis.
Gene expression assays
Tyrosinase and MHC-I mRNA expression were evaluated by use of custom-made
RT-PCR assays (TaqMan gene expression assays®, Applied Biosystems, Foster City,
CA, USA) designed by use of the manufacturer’s online design software (TaqMan
Custom Assay Design Tool®, Applied Biosystems, Foster City, CA, USA). The canine
tyrosinase assay was based on the clone CF02626293_m1, with the probe centered on the
exon 1-2 boundary. On the basis of this information, the software designed 72-bp assay.
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The equine assay was designed by use of the full-length equine tyrosinase mRNA
sequence (XM_001492560) with the probe centered over the exon 1-2 boundary. On the
basis of this information, the software designed a 73 bp assay. The canine MHC I assay
was designed by use of the full-length canine MHC-I clone (NM_001014378.1) with the
probe centered at the exon 3-4 boundary and an amplicon length of 97bp. The equine
MHC I assay was designed by use of the full-length equine MHC I clone
(NM_001082507.1) with the probe centered at the exon 4-5 boundary and an amplicon
length of 64 bp. For an endogenous control, the eukaryotic 18S ribosomal RNA, which
amplified a 69bp target centered on nucleotide 40 of clone Hs03003631_g1, was used.
Real Time PCR experiments
Quantitative RT-PCR assay was performed by use of a commercially available 1step kit (TaqMan RNA-to-Ct 1-Step Kit®, Applied Biosystems, Foster City, CA, USA).
In brief, reaction mixtures contained 6.375 μL of RNA template (approx. 1 μg), 0.375 μL
of reverse transcriptase enzyme mix, 7.5 μL of RT-PCR mix, and 0.75 μL of the
appropriate gene expression assay for a total volume of 15 μL. Reaction mixtures were
assembled in a 96-well plate in duplicate. Reaction conditions were as follows: reverse
transcription at 48°C for 15 minutes, activation of the DNA polymerase at 95°C for
10minutes, 60 cycles of PCR amplification consisting of denature at 95°C for 15 seconds,
and annealing and extension at 60°C for 1 minute. Real-time PCR reactions were
performed on a 96-well RT-PCR detection system (MyiQ Real-Time PCR Detection
System®, BioRad, Berkeley, CA, USA). Assay efficiency (90% to 105%) and linearity
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(r2 = 0.980) were confirmed prior to analysis. Final reaction products were run on 2.0%
agarose gels and stained with ethidium bromide for size verification.
Statistical and Data analysis
Gene expression analysis was performed by use of commercial software (iQ5
Real-time PCR Detection Optical System Software® version2.0, BioRad, Berkeley, CA,
USA). Baseline and threshold detection limits were automatically assigned via the system
software (STATA®, version 11.0, Data Analysis and Statistical Software, College
Station, TX, USA). With their appropriate placement visually verified. Threshold cycle
values for each sample were determined and normalized to the S18 reference gene Ct
value to obtain ΔΔCt. Standard deviations were obtained from duplicate runs and
normalized similarly. Tyrosinase expression was assayed in all samples by use of the
eukaryotic 18S ribosomal RNA as the reference gene. For all samples, relative
(normalized) tyrosinase expression was determined. Residual RNA samples were then
used to assay MHC I expression by use of the eukaryotic 18S ribosomal RNA as the
reference gene; however, not all samples contained adequate residual RNA to perform
this assay. The mean tyrosinase signal in normal tissue control samples from each species
was set to a baseline equal to 1 and then used to determine relative tyrosinase expression
in tumor samples. Relative MHC I expression was obtained similarly by use of the mean
control signal.
To evaluate the association between tumor histologic classification and relative
tyrosinase or MHC-I expression (ΔΔCt), canine tumors were grouped into benign,
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malignant, amelanotic, and non-melanocytic categories by a pathologist (SJN). Similarly,
equine tumors were grouped into benign, malignant, gray horse, and non-gray horse
categories. For canine malignant melanomas, tumor anatomic location (oral vs. other)
was also evaluated [14,15]. Normalized tyrosinase and MHC-I expression for histologic
tumor variants were analyzed by use of an ordinary least squares regression. All values
were evaluated for normality by use of the Shapiro-Wilk test. Non-normal distributions
were logarithmically transformed prior to analysis. Factors found to be significant in
univariate models were analyzed in a multivariate model. Tyrosinase or MHC I
expression was described as the sole independent variable analyzed for each outcome. To
assess for a significant correlation between the relative expression of tyrosinase and
MHC I, a 2-step procedure was used. The data were first analyzed to document a normal
distribution via the Shapiro-Wilk normality test. The Spearman correlation test was then
used on the non-normally distributed sample to assess correlation. Values of P <0.05
were considered significant for all comparisons.
Results
Canine tumor samples
For descriptive purposes and tyrosinase expression analysis, canine melanocytic
tumor samples were grouped into either primary oral or non-oral locations. Within each
group, tumor samples were further classified as either pigmented or amelanotic. For nonoral locations, tumors were also classified as either benign or malignant on the basis of
histologic analysis and mitotic index (mitotic figures/10 hpf ≥ 3). Twenty canine oral
melanoma samples were identified for analysis and included 3 labial, 4 maxillary, 3
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lingual, 6 mandibular, 2 soft palate, and 2 tonsillar locations. Histologic findings varied
from low-grade tumors to anaplastic and high-grade tumors. Six tumors had either
minimal or no obvious pigmentation and were thus classified as amelanotic; this was
confirmed with immunohistochemical analysis for s100, vimetin, or melan-A. Age at
diagnosis ranged from 7 to 16 years; mean age of onset was 11.1 years, and median age
of onset was 12.0 years. Dogs included 12 males and 8females, and most were mixed
breed.
Nineteen canine non-oral melanocytic tumor samples were selected, including 8
benign and 11 malignant samples. Benign melanocytic tumors included 7 cutaneous and
1 uveal locations. Malignant tumors included 2metastatic lymph node samples, 6
cutaneous (various locations) samples, and samples from 3 digital locations. Histologic
findings in malignant tumors were consistent with high-grade (anaplastic) tumors with a
mitotic index> 3 in all cases. Two of the malignant tumors (1 cutaneous and 1 digital)
were further characterized as having minimal to no observable pigmentation and thus
classified as amelanotic. Immunohistochemical analysis by use of combinations of S-100
or melan-A confirmed the diagnosis in poorly pigmented tumors. Age at diagnosis ranged
from 1 to 13 years, mean age of onset was 8.7 years, and median age of onset was 10
years. Dogs included 8 males and 11 females, and most were mixed breed.
Control samples were obtained from 10 dogs (4female and 6 male) with no
evidence of melanocytic tumors. Both oral and cutaneous normal tissues were collected.
The oral samples included 3 non-pigmented oral (buccal) mucosa samples and 1
pigmented oral mucosa sample. The cutaneous samples included 2nonpigmented skin
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samples and 2 pigmented skin samples. Two additional control samples were included
that represented non-melanocytic tumors (anaplastic sarcomas).These tumors were
negative for both melan-A and S-100 but positive for vimentin immunoreactivity. Mean
age of all control dogs was 9.1 years, with a median age of 9.0 years (range, 7 to 11
years).
Equine tumor samples
Eight equine tumor tissues were evaluated for tyrosinase expression. The tumor
samples were identified from both gray and non-gray horses. The gray horse tumor
samples included a uveal melanoma, 3 dermal melanomas (1 from a horse with
multifocal disease), and a lymph node with metastases. The non-gray horse samples
included 2 benign dermal melanomas and 1 morphologically malignant dermal
melanoma. The age of the gray horses ranged from 8 to 20 years (mean, 15.2 years;
median, 16 years).Three horses were female and 2 were male. Age of the non-gray horses
ranged from 11 to 18 years (mean, 13.3years; median, 11 years). All 3 non-gray horses
were male.
The control samples from normal equine tissues were obtained from gray and
non-gray horses with no external evidence of melanocytic tumors. Six equine control
tissues were collected from 3 horses. These included3 samples from pigmented skin (1
gray horse and 2 non-gray horses) and 3 samples from non-pigmented skin (1 gray and 2
non-gray horses).
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Canine tumor tyrosinase expression
For canine oral melanomas, values ranged from 4.06-fold to 4,810.90-fold (mean,
629.44-fold; median, 170.22-fold) relative expression, compared with the mean control
signal (1.0 ± 0.59). All tumors had high relative tyrosinase expression; the tumor with the
lowest expression (4.06 ± 0.15) nevertheless had substantially higher expression than the
control signal. This tumor was a low-grade oral melanoma located on the gingiva. The
tumor itself consisted of a small population of melanocytes with minimal criteria of
malignancy invasion. The highest tyrosinase expression for an oral melanoma (4,810.90
± 71.55) was found in a sparsely pigmented oral tumor with extremely aggressive
malignancy (Figure 4.1). Results of immunohistochemical analysis were positive for
melan-A, confirming the diagnosis of amelanotic melanoma.
For canine non-oral melanocytic tumors, relative tyrosinase expression ranged
from 21.65 to 2,135.32(mean, 338.34; median, 59.05), relative to the mean control signal.
The lowest tyrosinase expression (21.65± 4.13) was detected in a benign uveal
melanoma. The tumor had marked local invasion into the sclera; however, cellular
morphology was most consistent with a benign tumor, and the mitotic index was
extremely low (none observed). Highest expression was found in a malignant digital
melanoma (2,135.32 ± 51.26) with a high mitotic index, marked bone invasion, and
vascular invasion. Values are expressed as mean ± SEM.
Tyrosinase expression in all canine control samples was predictably low,
regardless of degree of pigmentation or anatomic location (oral vs. cutaneous).
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Expression for all samples ranged from 0.34 ± 0.34 for non-pigmented oral mucosa to
2.28 ± 0.48 for an anaplastic periorbital sarcoma (mean, 1.07; median, 0.89). Relative
expression of oral tumors ranged from 0.34 ± 0.34to 1.07 ± 0.31 and was not
significantly different from cutaneous samples that ranged from 0.71 for a non-pigmented
cutaneous sample to 2.28 for the anaplastic sarcoma. The remaining oral anaplastic
sarcoma had a similarly low expression (0.46 ± 0.19).
Ordinary least squares regression was used to evaluate the relationship between
tyrosinase expression and several covariates, including histologic classification (benign
vs. malignant), location (oral vs. non-oral), degree of pigmentation (melanotic vs.
amelanotic melanomas), and sample type (i.e., melanocytic tumors vs. control samples).
No significant (P = 0.84) difference in tyrosinase expression was found between benign
and malignant canine tumors. Similarly, there was no significant (P = 0.71) difference in
tyrosinase expression between oral and non-oral tumor locations. No significant (P
>0.84) difference in tyrosinase expression on the basis of the presence of pigmentation
was found between malignant melanotic (i.e., heavily pigmented) and malignant
amelanotic (non-pigmented) tumors. However, analysis of expression in melanocytic
tumors, compared with control tissues, identified a significant difference between the
groups. Melanocytic tumors had significantly (P <0.001) higher tyrosinase expression,
compared with control tissues.
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Equine tumor tyrosinase expression
All tumors, including benign, malignant, and multifocal tumors, had high relative
tyrosinase expression ranging from8.29 ± 1.84 to 219.57 ± 13.21 (mean, 93.2; median,
61.29). The lowest expression was found in a sparsely pigmented (essentially amelanotic)
melanoma from the ventral portion of the neck of a silver-colored horse. No special stains
were performed on this tumor to confirm histologic classification. The 2 highest
expressions were found in tumor samples obtained from gray horses with melanomatosis.
Tyrosinase expression in control tissues was low in both gray and non-gray horses,
regardless of pigmentation (mean, 1.0; median, 0.83).The lowest tyrosinase expression
was found in skin from a chestnut horse (0.22 ± 0.08), and the highest(1.96 ± 0.63) was
found in the pigmented (perirectal)skin of a chestnut horse.
Similar to dogs, an ordinary least squares regression was used to evaluate the
relationship between tyrosinase expression and, for horses, the covariates of coat color
and histologic classification. Horses were classified as gray or non-gray, and histologic
classification was recorded as benign or malignant on the basis of mitotic index and
morphology. Although the number of cases was small, no significant difference was
found in relative tyrosinase expression attributable to either coat color (P= 0.13) or tumor
histologic classification (P = 0.36). However, comparison of tyrosinase expression
between tumor and control tissues identified the predictably higher tyrosinase expression
in melanocytic tumors versus controls (P = 0.019).
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MHC I expression
All samples with adequate residual RNA (following tyrosinase expression) were
further assayed for MHC I expression. Canine tissue samples (n = 15) included 3
controls, 1 anaplastic sarcoma, 3 benign melanomas, and 8 malignant melanomas. Major
histocompatibility complex I expression in the canine normal control tissues ranged from
0.4 ± 0.02 for a non-pigmented cutaneous sample to 2.15± 0.11 for a non-pigmented oral
sample (mean, 1.0; median, 0.45). Expression in canine malignant tumor samples ranged
from a low value of 0.02 ± 0.002 for a metastatic lymph node lesion to a high value of
8.88 ± 0.68 for an oral malignant melanoma (mean, 2.53; median, 0.67). Benign canine
tumor samples had relatively low MHC-I expression, ranging from 0.40 ± 0.03 for an
ocular tumor to 1.06 ±0.12 for a cutaneous tumor (mean, 0.67; median, 0.57).No
significant associations were found between relative MHC-I expression and tumor
histologic classification (benign vs. malignant; P = 0.77), tumor location (oral vs. other; P
= 0.45), or sample type (control vs. tumor; P =0.11). Furthermore, to assess correlation
between relative tyrosinase and MHC-I expression, a Spearman correlation test was
performed. No significant (P = 0.61) correlation was detected between the expressions of
these 2 genes in this canine sample population.
Equine tissue samples (n = 6) that were evaluated for relative MHC I expression
included 3 control samples, 1 benign tumor, and 2 malignant tumors. Major
histocompatibility complex I expression in the normal equine tissues ranged from 0.18 ±
0.04 for the pigmented skin in a gray horse to 1.72 ± 0.36 for the non-pigmented skin
sample from a non-gray horse (mean, 1.0; median, 1.1). Relative expression in the tumor
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tissues differed widely, ranging from 1.42 ± 0.51 for a malignant cutaneous tumor in a
non-gray horse to 1,990.7 ±49.8 for a benign cutaneous tumor in a non-gray horse. The
small sample size and lack of values from gray horses precluded the evaluation of the
relationships between MHC-I expression and the described covariates.
Discussion

The goal of this study was to measure tyrosinase expression in a series of canine
and equine tumor samples obtained from the University of Tennessee College of
Veterinary Medicine pathology tumor database. The sample included 39 canine and 8
equine tumor samples, including benign, malignant, pigmented, and non-pigmented
variants. The RT-PCR method was chosen because a prior study8 and the present
authors’ exhaustive efforts had both failed to detect tyrosinase protein antigen via
immunohistochemical analysis by use of commercially available antibodies. The benefit
of the RT-PCR method is that it is extremely sensitive and allows the use of FFPE tissues
and fresh cytologic or histologic specimens to quickly determine both quantitative and
relative tyrosinase expression [16,17]. Furthermore, unlike IHC analysis, RT-PCR assay
can be used to determine the presence or absence of specific portions of target transcripts
that may be immunogenic [18,19].
In the present study, RT-PCR assay and tyrosinase mRNA-specific gene
expression assays were used to determine the presence or absence of appropriate targets
in the samples. The canine and equine expression assays included the sequences
orthologous to the human immunodominant region recognized by monoclonal antibodyT-
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311, and those sequences were thus detected by each assay [20]. Importantly, this
immunodominant region is thought to be required to elicit an antitumor response against
the tyrosinase tumor antigen [20–22]. In the present study, a modified RNA isolation
method that is useful in isolating RNA from FFPE tissues was also used. This resulted in
isolation of considerable amounts of high quality tumor RNA from each of the 48 tumors
and 16 control samples. The RNA samples were quantified via spectrophotometry and
assayed for quality via gel electrophoresis. Aliquots of each sample were then used for
the tyrosinase-specific gene expression assays.
The RT-PCR assays revealed high tyrosinase expression for most tumor samples.
Control tissues had extremely low tyrosinase expression. The high expression in
melanoma tumors and the relative lack of expression in normal tissues suggests a tissuerestricted expression pattern for this gene in horses and confirms previous data in dogs
[9,23,24]. On the basis of this information, tyrosinase-targeted immunotherapies may be
considered in horses. However, future studies are needed to examine tyrosinase
expression in additional control samples and other tumor types to more accurately define
expression patterns. Furthermore, because of small sample size, the present study was not
able to assess the prognostic importance of relative tyrosinase expression in melanocytic
tumors. Evaluation of additional cases will be helpful to determine the prognostic
importance of tyrosinase expression in general and in patients treated with the melanoma
vaccine (Oncept® Merial Limited, Athens, GA, USA).
Identification of tyrosinase expression, specifically the immunodominant
sequence of tyrosinase, provides proof of a target for immunotherapies targeting this
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protein in horses. The tyrosinase expression assays used in this project were designed to
amplify the exon 1-2boundary of tyrosinase and thus ensure the detection of transcripts
that have undergone appropriate splicing in this region. Importantly, this assay would not
recognize the presumably nonfunctional canine splice variant that lacks this boundary [9].
The exon 1-2 region of the tyrosinase protein encodes the catalytically active domain
required for tyrosinase function [1]. Inappropriate splicing or mutations within this region
could lead to pigmentation defects through loss of function (i.e., amelanotic tumors)
along with loss of the important immunodominant region. In fact, many humans with
disorders of pigmentation have mutations in this critical region [25]. Interestingly, in the
present study, no correlation was found between tyrosinase expression and the degree of
tumor pigmentation (i.e., melanotic vs. amelanotic tumors). In other words, similar
expression of the intact (and presumably) catalytically active (immunodominant) region
of tyrosinase was detected in pigmented and non-pigmented melanomas. This suggests
that mutations in other proteins involved in melanogenesis may be responsible for the
lack of pigmentation in canine amelanotic tumors. Additionally, the presence of the
immunodominant portion of the tyrosinase transcript in both melanotic and amelanotic
tumor samples support the use of anti-tyrosinase immunotherapies regardless of degree of
pigmentation.
Appropriate expression and function of the antigen-processing machinery are
required to elicit an effective immunologic response against tumor-specific antigens
[12,13]. Because deregulation of the antigen-processing machinery is common in tumors,
we evaluated the expression of MHC I mRNA as a representative of the antigen-
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processing machinery [12,13] Reduced or absent expression of the MHC I transcript in
these melanocytic tumors, compared with normal tissue, may suggest an impediment to
immunotherapies targeting the tyrosinase tumor antigen [12,13]. In the present study,
which had a small sample size, no consistent evidence was found of reduced or absent
MHC I expression in either normal or tumor samples. Unfortunately, sufficient residual
RNA was not available to assess expression in all samples. Furthermore, MHC I is only
one portion of the entire antigen-processing machinery [12,13]. Other proteins and genes
that appear to be commonly altered or deregulated in tumor cells include the TAP
(transporter associated with antigen processing) gene and proteins, β-microglobulin, a
variety of cellular chaperones, and other components of the antigen-processing
machinery [12,13]. These genes and proteins were not assessed in the present study but
would be logical candidates for subsequent studies. However, these initial data provide
further support for tyrosinase as an immunologic target in dogs. Future research would be
helpful to more fully assess the presence of expressional changes in genes or proteins
involved in antigen processing.
Another potential use of this RT-PCR technology is to complement traditional
staging tests (i.e., blood and lymph nodes can be screened for the presence of
tyrosinase).In human medicine, one of the first RT-PCR tests used in tumor-bearing
patients was designed to identify tyrosinase expression in the blood of patients with
melanoma [26]. Many studies have evaluated the prognostic importance of tyrosinase
expression in blood or lymph nodes and provided conflicting results [24,26–29]. In
general, results of most studies suggest that either a single high expression or changes in
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tyrosinase expression found in the blood of patients with melanoma can provide
important prognostic information related to the potential increased risk of metastatic
spread rather than as a tumor burden marker [27]. In light of the availability of an
immunotherapy that targets tyrosinase; further research is required to determine the
prognostic importance of tyrosinase expression in the blood of tumor-bearing dogs and
horses.
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Appendix of Tables and Figures

Figure 4.1..Photomicrograph of a section of a poorly pigmented amelanotic melanomain the oral mucosa
of a dog; the tumor had high tyrosinase mRNA expression, and results of immunohistochemical analysis
were positive for melan-A. H&E stain; bar =200 μm.
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Chapter 5 : Development of Immunologic Assays to Measure
Response in Horses Vaccinated with Xenogeneic Plasmid
DNA Encoding Human Tyrosinase.
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CHAPTER V
Brief explanatory statement:
This chapter is a slightly revised version of a manuscript that has been published in the
“Journal of Equine Veterinary Science” on October 2012. This is the third and final preclinical study before the testing of the tyrosinase anti-melanoma vaccine in its target
population: melanoma-bearing horses. It documents a pre-clinical study with this vaccine
in a small population of healthy horses and centers in reporting safety data and the
induction of an antigen-specific immune response throughout vaccination; as well as the
development of the proper immunoassays to evaluate and report this specific immune
response.
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Abstract
Xenogeneic plasmid DNA constructs have been developed and optimized for
immunotherapies targeting cancer in both humans and dogs. Specifically, plasmid vectors
containing the tumor antigen tyrosinase have demonstrated immunoreactivity and clinical
benefit in the treatment of melanocytic tumors in these species. Overexpression of
tyrosinase has also been noted in equine melanocytic tumors, supporting its role as a
valid tumor antigen in the horse. Vaccination with plasmid constructs containing
tyrosinase may thus have translational immunoreactivity in the treatment of equine
melanomas. Here, we describe a methodology that is highly sensitive and specific for the
detection of both humoral and cell-mediated immunoreactivity against tyrosinase in
equine patients. These antigen-specific immunoassays are used to measure the humoral
and cell-mediated responses in a cohort of horses vaccinated with xenogeneic plasmid
DNA encoding human tyrosinase. Serum humoral responses were measured using
standard enzyme-linked immunosorbent assay technique against the full-length
recombinant human tyrosinase protein. Peripheral blood mononuclear cells were
collected from vaccinated horses and stimulated with tyrosinase-specific peptides. Cell
mediated responses were then measured using a novel quantitative real-time polymerase
chain reaction technique to determine resultant interferon-g expression. All horses
developed significantly positive humoral and cell-mediated immune responses compared
with their individual pre-vaccination values. No adverse reactions or signs of
autoimmunity were detected. Vaccination with xenogeneic plasmid DNA expressing
tyrosinase appears to elicit tumor antigen-specific reactivity and should be evaluated in a
larger cohort of horses with melanocytic tumors.
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Introduction
Melanomas are among the most common tumors noted in horses, comprising
~15% of all skin tumors, second only to sarcoids [1-3]. These occur in all breeds and
colors but are most commonly seen in gray horses, reaching prevalence rates as high as
80% in older animals [2,3]. Tumors in affected horses are typically located in the perineal
region, under the tail, along the ventrum or extremities, or in visceral locations, with
metastases commonly noted at other cutaneous sites, lymph nodes, and viscera [4].
Overall, more than 90% of these tumors are benign at initial presentation, but up to twothirds can progress to overt malignant behavior if left untreated [4]. Surgical resection is
considered the mainstay of therapy, but curative surgery is rarely feasible because of
location. Other treatment options include radiation therapy, chemotherapy, and immune
therapy [1-4]. Prognosis is determined by initial tumor staging, histopathology, and
treatment options [4].Because most horses present with locally advanced, non-resectable
tumors, effective nonsurgical therapies are clearly needed to improve survival in these
patients. Immunotherapy may prove to fill this role in equine patients; recent work has
suggested that both local and systemic antitumor responses can be generated in tumorbearing horses [5-7].
Studies have been undertaken to elucidate the molecular basis of equine
melanoma as a comparative model for human melanocytic tumors. [8,9] For years,
veterinarians have been aware of the increased risk for tumor formation associated with
the loss of coat color due to graying. [10-13] Recent work has identified the genetic basis
for this premature graying as a 4.6-kb duplication in intron 6 of the STX17 gene, which
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leads to the overexpression of STX17and the neighboring gene NR4A3 [14]. Mutations
inmelanocortin-1 receptor (MC1R) signaling has also been studied to determine their role
in melanocytic tumor development [15-17]. Specifically, a single nucleotide
polymorphism in MC1R (C901T) has been linked to chestnut coat color and resultant low
risk of melanocytic tumor development [18]. A loss of function mutation (ADEx2) in the
agouti signaling protein, a known antagonist of MC1R, has been linked to black coat
color and an increased risk of melanoma formation [18]. In addition to the up-regulation
of downstream genes such as tyrosinase, enhanced signaling through the MC1R pathway
has also been shown to result in markedly increased expression of the NR4A nuclear
receptor subgroup in melanocytic cells. [19] As pointed out previously, overexpression of
NR4A3has been found in melanomas of gray horse, although it has not been directly
associated with the development of melanocytic tumors in humans or horses [20].
Understanding the role of melanogenic proteins in tumor formation allows for the
development of molecularly targeted therapies to treat patients with melanocytic tumors,
or in some cases, for prevention in those at risk for their development. A logical
molecular target is the protein tyrosinase, an enzyme that functions to catalyze the
hydroxylation of tyrosine to dihydroxyphenylalanine, a crucial step in melanin synthesis.
In general, tyrosinase expression is tightly controlled both spatially and temporally. [21]
In tumor tissue, however, tyrosinase expression appears to be constitutively increased
[21-23]. Furthermore, gray horses at increased risk of tumor formation (ADEx2) would
be expected to have elevated tyrosinase expression in their melanocytes due to enhanced
signaling from theMC1R pathway [18,21,24]. A novel methodology that can be used to
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target this tumor-specific antigen is the use of DNA vaccines encoding tyrosinase
[25,26]. These vaccines can be designed using xenogeneic DNA that is homologous to
the molecular target. Studies have shown that by using this approach, an effective antitumoral response, greater than that observed with syngeneic vaccines, can be generated
against the orthologous target [25,26]. In veterinary medicine, a United States
Department of Agriculture-licensed xenogeneic DNA vaccine encoding human tyrosinase
(HuTyr) is available for the treatment of canine melanoma.
This vaccine exploits the close homology of human and canine tyrosinase (92%)
to generate a tyrosinase-specific antitumor response [27]. In comparison, the equine
tyrosinase sequence shares 90% homology to the human sequence; based on this, crossreactivity of HuTyr DNA vaccine in the horse would be expected [28]. Herein, we
describe the first use of the HuTyr xenogeneic DNA vaccine in a cohort of normal horses
and the development of antigen-specific immunologic assays to document humoral and
cell-mediated responses to vaccination.
Materials and Methods

Institutional Animal Care and Use Committees reviewed and approved all
husbandry practices and animal procedures in this study.
Animals
Five healthy non-tumor-bearing female horses aged between 8 and 9 years were
used in this study and included two Quarter Horses and three Thoroughbred crosses.
These horses were determined to be healthy based on comprehensive physical
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examinations performed by both an equine board-certified specialist (J.T. Blackford) and
a certified veterinary oncologist (J.C.Phillips). Coat colors included bay (EQ-01 andEQ02), chestnut (EQ-03), gray (EQ-04), and black (EQ-05).
Vaccination Protocol
Horses were vaccinated in the pectoral muscles with 0.4 mL (100 ug) of a
xenogeneic plasmid DNA vaccine coding for HuTyr (Oncept®, Merial Limited, Athens,
GA, USA), using the VitaJet-3® (Bioject Inc, Portland, OR, USA) needle-free injector
device. The use of this device, for DNA plasmid intramuscular vaccinations, in horses
has been previously demonstrated [29]. The vaccination protocol consisted of four
biweekly injections on days 0, 14, 28, and 42. In one horse (EQ-01), a protocol extension
was included with additional vaccinations on days 146 and 160. This horse was selected
based on initial positive response and availability for repeat vaccination following
completion of the initial series. Visual evaluations of the vaccination sites were
performed daily over the 2 days following each vaccination to assess for possible local
site reactions. Vaccine dosage and schedule were selected to be comparable with the
currently recommended protocol for its use in dogs to treat malignant melanoma [25,27].
Sample Collection
Physical examinations and blood collections were performed on all patients
before each vaccination, and 2 (day56) and 6 weeks (day 86) after the final vaccine. In
EQ-01, additional examinations and collections were performed on days 146, 160, and
174. At each time point, 27 mL of blood was drawn into sodium heparin tubes (23 mL)
for peripheral blood mononuclear cell (PBMC) isolation and into serum separator tubes
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(4 mL) for serum separation. In EQ-01, the horse analyzed for anamnestic response, an
additional 3.5 L of blood was collected at day 56 for serum isolation. This serum was
stored at -80°C to serve as a positive control (for equine anti-HuTyr antibodies) in future
studies.
Measurement of Humoral Immune Response
Serum was separated by centrifugation at 1,200xg and stored at -20°C until use.
Standard enzyme-linked immunosorbent assays were used to determine anti-HuTyr
antibodies according to published methods [27]. In brief, Immulon® (Thermo Fisher
Scientific, Pittsburgh, PA, USA) microtiter plates were coated overnight at 4°C with 50
mL/well (0.05 mg) of full-length recombinant HuTyr protein (Abnova Corporation,
Jhongli City, Taiwan, China) and then washed with phosphate-buffered saline
(PBS)/Tween (0.05%). Patient serum (50 mL/well) was added as serial dilutions from
1:20-1:540, incubated for 1 hour at 37°C, and then washed. A secondary horseradish
peroxidase-conjugated goat anti-horse Immunoglobulin G (IgGT) or Immunoglobulin M
(IgM) antibody (Bethyl Laboratories, Montgomery, TX, USA) was added (50 mL of a
1:500 dilution), incubated, washed, and then developed using a 3,3’,5,5”tetramethylbenzidine (TMB) substrate solution (Thermo Fisher Scientific, Pittsburgh,
PA, USA).Reactions were stopped after approximately 10 minutes by adding 50 mL/well
of 0.18M H2SO4. The OD450 values were measured using theELx800® (Bio-Tek
Instruments, Winooski, VT, USA) microplate reader instrument. Serum from EQ-01 was
used as both an inner-plate positive control and to normalize between plates for all equine
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samples. For negative controls, primary antibody (serum) was not added. Reactions were
run in triplicate with average (OD450) results reported, using negative controls as blanks.
Measurement of Cellular Immune Response
Isolation and Stimulation of PBMCs: Samples were diluted with equal volumes of
PBS, overlaid in Ficoll-Paque (GE Healthcare, Piscataway, NJ, USA), and separated by
density gradient centrifugation. The mononuclear layer was isolated and washed with
sterile PBS. Cells were resuspended in Roswell Park Memorial Institute (RPMI) cell
culture media (Cellgro, Mediatech, Manassas, VA, USA) containing 10% fetal bovine
serum and antibiotics. Cells were then aliquoted (2 mL/well) into sterile cell culture
plates (Costar, Corning Life Science, Corning, NY, USA) and placed in a CO2 incubator
at 37°C. To determine cellular reactivity to HuTyr, PBMCs were incubated with
synthetic peptides (NeoBioScience, Cambridge, MA, USA) encoding HuTyr. The fulllength protein was divided into 35 peptides with each overlapping the neighboring
sequence by five residues, as previously described [28].Peptide purity (>75%) was
selected to include a mixture of 8mers to a maximum of 20mers. Lyophilized peptides
were reconstituted in dimethyl sulfoxide/PBS and then run through a purifying column
(PD-MiniTrap G-10®, GE Healthcare, Piscataway, NJ, USA). Three peptide pools were
created (Tyr1, Tyr2, and Tyr3), each containing 11-12peptides and overlapping other
pools by 20 amino acids (Figure 5.1). Aliquots (10 mg/2 mL well) from each peptide
pool were added to separate wells in the cell culture plates containing PBMCs and
incubated (37°C) for 16 hours (time optimized for interferon-g expression, data not
shown).Positive controls were incubated with the nonspecific mitogen concanavalin A
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(GE Healthcare, Piscataway, NJ, USA) (4mg/2 mL well), whereas negative controls were
incubated with a BLASTSM-queried random peptide sequence [30].
RNA Isolation: After incubation, cells were pelleted and washed with fresh
media. Total RNA was isolated using the SV Total RNA Isolation Kit® (Promega,
Madison, WI, USA) according to manufacturer’s specifications, which included a DNAse
treatment step designed to substantially reduce genomic DNA contamination. The yield
of total RNA was determined spectrophotometrically (NanoDrop ND-1000®,
Wilmington, DE, USA) at 260 nm, whereas purity was estimated from the relative
absorbance at 230, 260, and 280 nm (i.e., A260/A280and A260/A230). Samples were
stored at -80°C pending analysis.
Gene Expression Assays: Cell-mediated reactivity to HuTyr epitope exposure was
measured by determining IFN-γ mRNA production from stimulated cells. Values were
normalized to total CD4 andCD8 mRNA expression to account for varying numbers of
αβ T lymphocytes between samples. Preliminary work in our laboratory documented a
linear correlation between CD8 mRNA expression and absolute number of CD8β cells.
Similar results have been found for CD4 mRNA expression and absolute CD4 cell
number (data not shown), as previously reported [31,32]. RT-PCR was performed using
TaqMan gene expression assays® (Applied Biosystems, Foster City, CA, USA) designed
by use of the manufacturer’s online design software (TaqMan Custom Assay Design
Tool®, Applied Biosystems, Foster City, CA, USA). Target sequences included fulllength

equine

IFN-γ

(NM_001081949),

CD4

(XM_001497051.2),

and

CD8β

115

(XM_001497872) mRNA. Probes were centered at exon 3-4, 67, and 2-3 boundaries,
respectively (Table 5.1).
Quantitative Real-Time PCR: RNA was reverse transcribed to cDNA using a
commercial kit (High Capacity cDNA Reverse Transcription kit®, Applied Biosystems,
Foster, CA, USA) and then pre-amplified using the TaqMan PreAmp Master Mix kit®
(Applied Biosystems, Foster, CA, USA) according to the manufacturer’s specifications.
Real Time PCR reactions (20 µL) were conducted on a 96-well RT-PCR detection
system (MyiQ Real-Time PCR Detection System®, BioRad, Berkeley, CA, USA) and in
brief included the following: 9 µL of diluted pre- amplified cDNA, 10 µL of TaqMan
Gene Expression Master Mix® (Applied Biosystems, Foster, CA, USA), and 1 µL of the
appropriate TaqMan gene expression assay® (Applied Biosystems, Foster, CA, USA).
Standard curves were created using known amounts of cDNA for each run. Samples were
run in duplicate for each gene. Cycling parameters were set at 50°C for 2 minutes, 95°C
for 10minutes, followed by 40 cycles at 95°C for 15 seconds and60°C for 1 minute.
Baseline and threshold detection levels were automatically assigned by the MyiQ
software, and then visually verified. Data analysis was performed using the iQ5 Optical
System Software® (iQ5 Real-time PCR Detection Optical System Software® version2.0,
BioRad, Berkeley, CA, USA). Duplicate results (Ct values) were averaged and plotted on
their corresponding standard curve to obtain a copy number. Assay efficiency (90%105%) and linearity (r2 = 0.980) were confirmed before analysis. Final reaction products
were run on 2.0% agarose gels and visualized with ethidium bromide for size
verification.
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Stimulation Index: For each sample, absolute IFN-γ mRNA copy number was
normalized to total CD4 and CD8 mRNA copy numbers; results were reported in the
form of a stimulation index(SI), as previously described [31,32]. The measure of SI for
HuTyr reactivity (TyrSI) was calculated as the ratio of IFN-γ copy number when PBMCs
were incubated with each of the three separate pools of HuTyr peptides (XTyr =
ΣTyr1,Tyr2,Tyr3) divided by IFN-γ copy number when PBMCs were incubated with
random peptides (YNC). In brief, TyrSI = XTyr/YNC.
Statistical Analyses
Data were first evaluated for normality using the Shapiro-Wilks normality test
[33]. Data did not follow a normal distribution; therefore, the nonparametric sign test of
matched pairs was used to compare the cellular and humoral immunoreactivity values
before and after vaccination [34]. A significant difference was defined as P < 0.05.A
positive immunological response threshold was then defined as greater than three
standard deviations above the group’s baseline mean value. Similar methodology was
used to determine whether there was a significant difference in the cellular reactivity in
different peptide pools. The Simes method for multiple hypothesis testing was used to
correct for multiple comparisons [35]. All statistical analyses were performed using
STATA 11.1 Data Analysis and Statistical Software® (Statistical Analysis Systems
Institute, Carey, NC, USA).
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Results
Humoral Response
A gradually increasing response trend was noted in the antibody levels (IgG) of
all horses in response to HuTyr vaccination, as measured by a tyrosinase-specific indirect
enzyme-linked immunosorbent assay (Figure 5.2A). The humoral positivity threshold,
above which observed values would be considered positive for the induction of a
significant immune response, was set three standard deviations above the group’s
baseline mean value (x̄ = 0.13, σ = 0.02) at OD450= 0.18. Two of the horses (EQ-03 and
EQ-04) showed a positive response as early as day 28, with the remaining horses having
positive responses by the completion of the vaccination series (day 56). Overall, there
were significant (P = 0.03) increases in humoral response that ranged from a two- to
threefold increase in the post-vaccination sera at day 56 compared with the prevaccination sera at baseline on day 0. Additional humoral time-points were evaluated in
EQ-01 to determine anamnestic response. The highest value (OD450= 0.666) was noted 2
weeks after completion of the booster series, an approximate fivefold elevation over the
baseline value (Figure 5.3A). HuTyr-specific IgM reactivity was also evaluated in EQ-01
showing, similar to IgG, a gradual increase throughout the initial vaccination protocol,
with the maximal response (OD450= 2.25) noted 2 weeks after completion of the initial
vaccination series (day 56), an increase of 25% over the baseline value. Within a month
(day 86), this value had decreased below the initial baseline value, as expected for an
IgM primary antigen response (data not shown).
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Cell-Mediated Response
Similar to humoral assays, a positivity threshold (TyrSI = 3.8) was set at three
standard deviations above the group’s mean baseline value (x̄ = 2.2, σ = 0.53). Positive
cellular reactivity was seen in three of the five vaccinated horses by day 28 and in four of
the five horses by the fourth vaccination point (day 42). Two weeks after completion of
the vaccination scheme (day 56), the remaining horse (EQ-05) also surpassed the
threshold (Figure 5.2B). Analysis of EQ-01 anamnestic response noted a dramatic drop in
immunoreactivity when vaccination stimuli stopped, with values below the threshold
when evaluated at day 146. When vaccination was reinstituted (boosters),
immunoreactivity values increased to near the threshold limit by day 160 and clearly
above it by last recheck at day 174 (TyrSI = 7.6). Overall, the degree of HuTyr-specific
cellular response seen in vaccinated horses ranged from 2- to 29-fold higher compared
with pre-vaccination levels (with a mean fold increase of 8.9) (Figure 5.3B).These values
represent a significant increase compared with pre-vaccination baseline value (P = 0.03).
To further describe the antigenicity of the different tyrosinase epitopes in horses,
we examined the normalized IFN-γ expression in each of the three individual peptide
pools at the end of the vaccination protocol (day 56). Results of this form of epitope
mapping are shown in Fig. 5.4 for each individual horse. Peptide pool 1 (Tyr1) showed
most reactivity in three of the five horses (EQ-01, EQ-02, EQ-05), whereas peptide pool
2 showed the highest reactivity in the remaining two horses (EQ-03, EQ-04). However,
when comparing all five horses as a group, therewas no significant difference in the
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median IFN-γ expression between any of the peptide pools (Tyr1/Tyr2 = 0.239,
Tyr1/Tyr3 = 0.449, andTyr2/Tyr3 = 0.044; critical P value = .017).
Discussion

Herein, we describe a pilot study evaluating the use of a tyrosinase-specific DNA
plasmid xenogeneic vaccine in normal horses and the development of the appropriate
surrogate assays needed for monitoring the specific immune response. This plasmid is
designed to be taken up by muscle cells and then transcribed [36]. The processed protein
would then be expected to generate a self-tolerant tyrosinase-specific immune response.
Similar to previous reports evaluating this xenogeneic vaccine, the immunoreactivity
measured was to the HuTyr protein and not to the orthologous equine protein [18,25,27].
Conceptually, the purpose of xenogeneic vaccination is to induce cross-reactive immune
responses in tumor-bearing horses and/or overcome auto-regulatory mechanisms that
have allowed tumors to escape immunosurveillance [37]. However, reactivity to the
xenogeneic protein is routinely measured as an immunologic endpoint, and initial
evidence suggests a correlation between these values and clinical outcome [25,27].
Vaccinated horses in this report were evaluated to assess local site reactions and
to determine magnitude, timing, and persistence of both humoral and cell-mediated
reactivity to HuTyr using specifically developed immunoassays. With respect to reactions
at the vaccine site; although most horses experienced them, they appeared mild,
consisting of dependent edema that resolved without therapy within 48 hours after
vaccination. Furthermore, no appreciable pain response was seen in vaccinated horses;
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however, some appeared to be startled by the actuation of the device at the time of
injection. Vaccination appeared to successfully elicit both humoral and cell-mediated
reactivity to the HuTyr protein in this small cohort. Based on defined threshold values, all
horses exhibited statistically significant positive humoral responses to vaccination (P
=0.03). Maximal immunoreactivity was noted 2 weeks after completion of the
vaccination protocol, with these levels falling below threshold by week 6 postvaccination (day 86). Booster vaccination given to one horse (EQ-01) resulted in the
predicted renewed rapid production of tyrosinase-specific antibodies. These results are
consistent with an appropriate immune response to the (expected) transient expression of
a plasmid vector. Because these patients were “healthy animals,” they lacked the
presence of a consistent antigenic stimulus (i.e., tyrosinase expressing tumor) that may
help to maintain elevated humoral and cellular responses. Alternatively, in tumor-bearing
patients, it may actually be more difficult to break tolerance compared with healthy
animals due to an altered immunologic status (tumor tolerance). However, Liao et al.
evaluated the use of this tyrosinase-specific vaccine in tumor-bearing dogs and observed
increasing levels of tyrosinase-specific antibody in a portion of the dogs up to 10 months
post-vaccination, although not all tumor-bearing dogs developed a humoral response
[27].Although a consistent antigenic stimulus may thus be important for maintaining
humoral response, it is not the sole determinant of either its presence or initial magnitude.
Humoral-specific responses are relatively easy to measure; however, cellular
immune responses are thought to be the most important mediator of tumor regression,
especially for intracellular antigens such as tyrosinase. In this context, tumor-specific
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immunotherapies that depend on cytotoxic T-cell response require the development of
assays to monitor their stimulation and tumor-specific reactivity [38-40]. The most
common methodology used to document lymphocytic cell reactivity is the indirect
measurement of cytokine production. In this approach, isolated PBMCs are exposed to
peptide antigens and their recognition by T lymphocytes (mainly CD8+ and CD4+)
results in the production of various cytokines that can be quantified as a measure of
reactivity. IFN-γ is the most commonly measured marker of antitumor-specific T-cell
activation and has an advantage over interleukin (IL)-2, IL-4,and IL-12 in that it is not
secreted by non-stimulated PBMCs [31]. A variety of methods are available to measure T
lymphocyte-mediated cytokine production, including enzyme-linked immunosorbent spot
technique, intracellular cytokine staining with flowcytometric cellular enumeration, and
RT-PCR. Although enzyme-linked immunosorbent spot is a sensitive technique and has
been successfully used to evaluate cellular response to HuTyr in dogs, it is at best semiquantitative and does not allow for enumeration of cell type [30]. In contrast,
flowcytometry does allow for this enumeration and is generally less sensitive than other
techniques. Our initial efforts to quantify cellular reactivity used flowcytometry to
measure IFN-γ production. However, in our study, this technique lacked the sensitivity to
produce reliable measurements (data not shown). RT-PCR works by detecting cytokine
mRNA production and thus is a highly sensitive technique. Although it does not allow for
cellular enumeration, results can be normalized using a variety of targets including
CD4and CD8 mRNA expression [31,36-39]. Furthermore, the use of standard curves for
calibration and other optimization techniques allows for consistency of assay results
[31,32].
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Cellular reactivity was therefore measured using RT-PCR detection of IFN-γ
mRNA. Using this approach, all horses exhibited statistically significant cellular
reactivity to HuTyr epitopes at the end of the vaccination protocol when compared with
pre-vaccination levels (P =0.03). As expected, the variability of this response between
patients was high; however, the variability within a specific patient was low. Patientspecific variability can be assessed using the standard deviation of duplicates and relative
TyrSI values at different time points in the protocol. Figure 2b shows a TyrSI that is
stable to increasing (between time points) and a low standard deviation of duplicates.
Wide variability in the immune response is an expected finding in studies of this
nature due to both small sample size and the heterogeneity of outbred populations.
Sample size is typically limited by the cost of the assays used to monitor the immune
response, which is especially true when dealing with large animal patients, such as
horses. Heterogeneous populations, however, can lead to important insights on the
mechanism underlying immune response. For instance, the humoral (OD450= 0.20) and
cellular (TyrSI = 4.2) responses of one horse (EQ-05) were only marginally above the
positive threshold by the end of the vaccination protocol. Although this horse was
believed to be a non-pregnant mare, 5 months after completion of the vaccination series,
she foaled a normal foal. Unfortunately, no information is available on the effect of
pregnancy on either timing or magnitude of responses to immunotherapy in horses;
although information suggests that the immune response of the mare may be significantly
repressed during pregnancy [41,42]. Interestingly, the horse with the second lowest
cellular response (EQ-04, TyrSI = 4.8) developed the second highest humoral response of
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the group (OD450 ¼ 0.32), providing further evidence of the variability that can be seen
with plasmid-mediated immunotherapy.
By evaluating the SI in each of the individual epitope pools, our goal was to
identify the most immunogenic pool. Sequence analysis would suggest that this would be
peptide pool 2, based on the comparative number of sequence differences between human
and equine tyrosinase (Figure 1). In humans, it is also known that this region of the
tyrosinase sequence contains the immunodominant epitopes of the protein [43]. Our
previous work had also documented the overexpression of the sequence within this pool
in equine melanocytic tumors [23]. Statistical analysis, however, failed to identify a
significant difference in immune reactivity between the three peptide pools. Given the
outbred nature of the horse, further refinement of the equine-specific epitope of HuTyr
would require a larger sample size and more refined peptide pools.
The etiology of melanoma in horses is unknown; however, information on some
risk factors is available. Expressional changes in the genes STX17, NR4A3, and
MC1Rhave been linked with increased risk for melanocytic tumor development in horses
[14,18,24]. Although each of these changes is likely important, the deregulation of MC1R
in particular results in the overexpression of genes such as tyrosinase. The overexpression
and tumor-specificity of tyrosinase makes it an excellent candidate for targeted
immunotherapies [23-27]. Traditional syngeneic vaccines targeting tumor-specific
antigens result in relatively poor immunologic responses due to self-tolerance [37]. In
contrast, the use of a xenogeneic HuTyr DNA vaccine can overcome self-tolerance by
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taking advantage of the close homology between the human and equine tyrosinase
sequence and ultimately induce a strong tumor antigen-specific immune response.
A larger field study in horses with melanocytic tumors, however, is required to
evaluate the clinical activity of this vaccine and to confirm whether tumor-specific
immune responses occur. These studies could also evaluate changes in a wider cytokine
profile (e.g., IL-2, IL-12, IL-10, and TGF-β) as well as analyze the local intratumoral
changes (i.e., changes in the proportions and nature of the tumor infiltrating lymphocytic
component) in response to vaccination.
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Appendix

of Tables and Figures

Table 5.1. TaqMan primers and probes used for qRT-PCR measurement of gene expression of both target
and normalizer genes.

Table 5.1

Primers and

Amplicon

Gene name

probes

Sequence

length

Interferon
gamma

E-IFNγ-F

5’-AGCAGCACCAGCAAGCT-3’

76bp

E-IFNγ-R

5’-CTTTGCGCTGGACCTTCAG-3’

E-IFNγ-P

5’-(FAM)CAGATTCCGGTAAATGAT(TAMRA)-3’

E-CD4-F

5’-ACCAGAAGACACTGGTGTTCAACATAA-3’

E-CD4-R

5’-AGTCTCTCGCACAGTCTATGCGAAAGAGGG-3’

E-CD4-P

5’-(FAM)ACATCTTGGTGCTGGCTTTCCAGAA(TAMRA)-3’

E-CD8-F

5’-CTGACTTTCGGGACAGGAACTC-3’

E-CD8-R

5’-CGGGCAGTGGTGGGAAA-3’

CD4

CD8

82bp

59bp

5’-(FAM)ACATCAACCACACTTAGCC(TAMRA)-3’
E-CD8-P
F: Forward primer, R: Reverse primer, P: Taq-Man probe, FAM: 6-carboxy-fluorescein, TAMRA:
tetramethylrhodamine.
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Figure 5.1. HuTyr pool scheme. Human tyrosinase protein sequence divided into 3 different peptide
overlapping pools used for in vitro stimulation of isolated PBMCs (note that there is a 20-amino acid overlap
from pool to pool). The comparative alignment and predicted tyrosinase protein sequences from human and
equine are also shown. Equine sequence shows 90% predicted sequence homology to the human sequence.
Deviations from the human sequence are noted in red.
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Figure 5.2. Immune response trends in horses treated with HuTyr vaccine. (A) IgG humoral response
trends at 1:20 dilutions, positivity threshold (dashed line) was set at anOD450 = 0.18. (B) Cellular immune
response trends; positivity threshold (dashed line) was set at a TyrSI= 3.8. Arrows represent vaccination
days.
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Figure 5.3. Anamnestic immune response trends in EQ-01. (A) Graph showing the anamnestic humoral
response to HuTyr IgG response to HuTyr vaccination. (B) Graph showing the anamnestic cellular
response to HuTyr vaccination. Positivity thresholds are denoted by dashed lines and are set at an OD450=
0.18 for humoral response and a TyrSI= 3.8 for cellular immune response. Arrows represent vaccination
days.
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Figure 5.4. Immunoreactivity to individual HuTyr peptide pools as measured at the end of the vaccination
protocol on day 56 by IFN-γ expression normalized to CD4and CD8 expression in all horses. PC = positive
control (ConA); NC = negative control (random peptide).
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Chapter 6 : Safety and Immunoreactivity of a Human
Tyrosinase Anti-Melanoma Vaccine in Tumor-Bearing
Horses
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CHAPTER VI
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Abstract
Melanomas are among the most common skin tumors in horses, with prevalence rates
reaching as high as 80% in adult gray horses. The great majority of melanocytic tumors
are benign at initial presentation; however, if left untreated up to 2/3 can progress to overt
malignant behavior, which can significantly affect the horse’s performance and
eventually lead to death. Despite the wide availability of measures of local control, there
are currently no systemic therapies that can effectively prevent spread, or treat metastatic
or locally advanced/non-resectable melanoma in horses. Immunotherapy using plasmid
DNA constructs encoding xenogeneic forms of the antigen tyrosinase, have demonstrated
immunoreactivity and clinical benefit in the treatment of melanomas in humans and dogs.
Our previous work established the scientific basis for the immunologic targeting of
tyrosinase in equine melanoma, the optimal vaccination technique, the proper
methodology to assess tyrosinase-specific immune response, and provided important data
on safety and immunoreactivity of the vector. Here we describe the first dose escalation
trial using a human tyrosinase plasmid DNA vaccine in tumor-bearing horses. The results
of this trial documented that vaccination is able to induce a significant tyrosinase-specific
systemic immune response, both humoral (p =0.001) and cellular (p =0.0004) in treated
horses; as well as a significant local intratumoral immune response, as measured by
significant increases in intratumoral CD8+ T cells (p <0.0001) and decreases in
intratumoral regulatory T cells (p =0.002). Vaccine administration was associated with
statistically significant tumor burden reductions (p <0.0001). No significant difference in
clinical or immune responses was observed between dosing cohorts. No significant
adverse events were observed, and the vaccine appeared safe and well tolerated in horses.
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Introduction
Melanomas are among the most common tumors noted in horses, comprising
~15% of all skin tumors, second only to sarcoids. [1-3] This occur in all breeds and
colors but are most commonly seen in gray horses, reaching prevalence rates as high as
80% in older animals. [2,3] The overwhelming majority of melanocytic tumors are
benign at initial presentation; however, if left untreated up to 2/3 can progress to overt
malignant behavior, which can significantly affect the horse’s performance and
eventually lead to death, thus resulting in a considerable health and economic impact in
the equine community. Despite the high frequency of these tumors, there is currently no
systemic treatment that can effectively manage metastatic spread, hold on progression.
Surgical resection is considered the mainstay of therapy, but curative surgery is rarely
feasible because of location. Other treatment options include radiation therapy,
chemotherapy, and immune therapy [1-4]. Prognosis is determined by initial tumor
staging, histopathology, and treatment options [4]. Because most horses present with
locally advanced, non-resectable tumors, effective nonsurgical therapies are clearly
needed to improve survival in these patients. Immunotherapy may prove to fill this role in
equine patients; recent work has suggested that both local and systemic antitumor
responses can be generated in tumor-bearing horses [5-7].
Studies have been undertaken to elucidate the molecular basis of equine
melanoma as a comparative model for human melanocytic tumors [8,9]. For years,
veterinarians have been aware of the increased risk for tumor formation associated with
the loss of coat color due to graying [10-13]. Recent work has identified the genetic basis
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for this premature graying as a 4.6-kb duplication in intron 6 of the STX17 gene, which
leads to the overexpression of STX17 and the neighboring gene NR4A3 [14]. Mutations
in melanocortin-1 receptor (MC1R) signaling have also been studied to determine their
role in melanocytic tumor development [15-17]. Specifically, a single nucleotide
polymorphism in MC1R (C901T) has been linked to chestnut coat color and resultant low
risk of melanocytic tumor development [18]. A loss of function mutation (ADEx2) in the
agouti signaling protein, a known antagonist of MC1R, has been linked to black coat
color and an increased risk of melanoma formation [18]. In addition to the upregulation
of downstream genes such as tyrosinase, enhanced signaling through the MC1R pathway
has also been shown to result in markedly increased expression of the NR4A nuclear
receptor subgroup in melanocytic cells [19]. As pointed out previously, overexpression of
NR4A3 has been found in melanomas of gray horse, although it has not been directly
associated with the development of melanocytic tumors in humans or horses [20].
Understanding the role of melanogenic proteins in tumor formation allows for the
development of molecularly targeted therapies to treat patients with melanocytic tumors,
or in some cases, for prevention in those at risk for their development. A logical
molecular target is the protein tyrosinase. Tyrosinase is a prototypical melanocyte
differentiation antigen which acts as an enzyme that functions to catalyze the
hydroxylation of tyrosine to dihydroxyphenylalanine, a crucial and tightly controlled
(both spatially and temporally) step in melanin synthesis. [21] In tumor tissue, however,
tyrosinase expression appears to be constitutively increased [21-23]. Furthermore, gray
horses at increased risk of tumor formation (ADEx2) would be expected to have elevated
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tyrosinase expression in their melanocytes due to enhanced signaling from the MC1R
pathway [18,21,24]. Nonetheless, there is large evidence that this self-protein can be
recognized by T cells from melanoma patients [25-27] and measurable CD8+ T-cell
responses have been induced against individual TYR epitopes using synthetic peptides.
[28,29]
Various methods for vaccination have been used to immunize against tyrosinase.
And although peptide vaccines have shown some efficacy, these type of vaccines are
mainly limited by the restriction that peptides of the selected protein/antigen can only be
used individually; and so, often these vaccines require adjuvants (e.g., GM-CSF,
Freund’s adjuvant) to elicit an important immune response in vaccinated patients. [28-31]
Logically, the utilization of the full-length of the protein/antigen would be more
advantageous than just using individual peptides because it has potential to present
multiple epitopes. [28] Immunization with DNA instead allows to do precisely this, by
presenting the full-length of the complementary DNA sequence which codes for the
protein/antigen properly loaded in a plasmid. [29] Other markedly important advantages
of DNA immunization are the ease of engineering a non-infectious vector, its relative
efficiency, and low cost of manufacture as well as the presence of unmethylated CpG
motifs (immunostimulatory sequences) in the vector backbone which stimulate the innate
immune system through TLR9 ligation and so act as a potent immunological adjuvant.
[28-32]
Multiple pre-clinical studies using B16 mouse models of melanoma have shown
that immunization with xenogeneic (human) DNA encoding for melanocyte
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differentiation self-antigens of the tyrosinase family (e.g., tyrosinase, gp100, gp75, TRP1, TRP-2) was an effective strategy for overcoming immunologic tolerance (which
frequently constrains responses to poorly immunogenic self-proteins) and inducing
cancer immunity that resulted in protection from syngeneic tumor challenge as well as
rapid and extensive depigmentation of hair. [29,33-36] This same approach of using
xenogeneic tyrosinase have also been implemented in human melanoma patients with
promising results [28] And so, vaccines can be designed using xenogeneic DNA that is
homologous to the molecular target. Studies have shown that by using this approach, an
effective antitumoral response, greater than that observed with syngeneic vaccines, can
be generated against the orthologous target [37,38].
In veterinary medicine, after a series of successful clinical trials [37,39,40], the
United States Department of Agriculture licensed a xenogeneic DNA vaccine encoding
human tyrosinase and delivered with a pING plasmid for the treatment of canine
melanoma. The results from these clinical trials and several later studies evidenced a
considerable increase in the survival time of vaccinated dogs, even in patients with
already identified metastatic disease. [37,39,42] This vaccine exploits the close homology
of human and canine tyrosinase (92%) to generate a tyrosinase-specific antitumor
response [40]. In comparison, the equine tyrosinase sequence shares 90% homology to
the human sequence; based on this, cross-reactivity of HuTyr DNA vaccine in the horse
would be expected [41].
Over the past four years we have established the necessary groundwork for the
evaluation of the pING-HuTyr vaccine in melanoma bearing horses. Our initial work
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evaluated the use of needle-free injectors for the intramuscular vaccination of horses.
Vaccinations in the anterior pectoral muscles were determined to be a safe and effective
approach for the delivery of DNA plasmid vaccinations. [43] Evaluation of tyrosinase
expression in equine tissues was then performed to determine the tissue-specific
expression of this transcript. [23] Tyrosinase was notably found to be overexpressed in all
variants and locations of melanocytic tumors found in our study population. Furthermore,
no detectable expression was found in normal skin or mucosal tissue regardless of base
coat color or degree of pigmentation of mucosal tissue. [23] Lastly, in our final
preclinical study, we evaluated the safety and immunoreactivity of the pING-HuTyr
DNA plasmid vaccine in a cohort of normal non-tumor bearing horses; and developed the
appropriate immunoassays to measure their specific immune response to this particular
vaccine. [44] No signs of acute or late toxicity were noted in treated patients. Tyrosinasespecific humoral responses were seen in all patients. A novel methodology was designed
to measure tyrosinase-specific cell mediated reactivity. This methodology was
demonstrated to be highly sensitive with dynamic range that surpasses previous
technology. Results were also found to be highly specific for measuring the immunologic
response to defined epitopes. Cell-mediated responses were also seen in all patients.
In summary, we established the scientific basis for the immunologic targeting of
tyrosinase in equine melanoma, the technique used to vaccinate patients, and the
methodology used to determine response to vaccination. [23,43,44] It is with this
acquired knowledge that we here consequently conducted a trial in equine melanomabearing patients. Herein, we utilize a combination of humoral and cell-mediated antigen

140

specific immunoassays to document the immune response of these cohorts of tumor
bearing horses. Finally, we also included in our analysis the intratumoral evaluation of
potential changes in the tumor infiltrating lymphocyte population (especially in the
cytotoxic CD8 T cell to regulatory T cell ratio) in response to vaccination, which resent
studies have shown as prognostic for both immune and clinical responses in several
tumor types, including melanomas. [45-51]
Materials and Methods

Institutional Animal Care and Use Committees from both The University of
Tennessee and Lincoln Memorial University reviewed and approved all husbandry
practices and animal procedures in this study.
Patient Population

10 melanoma-bearing grey horses age between 11 and 24 years (mean age of 16
years) were included in this study, from which 6 were males and 4 were females. Breeds
included three Arabians, two Paso Finos, two Irish Draught Horses and one of each,
Andalucian, Oldenburg and American Quarter Horse (Table 6.1). Patient inclusion
criteria for the study included a clinical diagnosis of cutaneous melanoma at any given
location/s (Figure 6.1) as performed by both an equine board-certified specialist (J.T.
Blackford) and a certified veterinary oncologist (J.C. Phillips), measurable external tumor
burden >3 cm to allow for serial biopsying, no other significant concurrent disease or
history of immune-mediated disease, no concurrent anti-cancer treatment of any kind
(including NSAIDs), and a written owner consent. Furthermore, patient tumor grade was
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defined according to a modified classification system on a scale from 1 to 5, as
previously described. [52]
Vaccine Information

This xenogenic vaccine consists of human tyrosinase cDNA inserted in the pING
plasmid vector, which contains a cytomegalovirus promoter and kanamycin resistance
selection marker. [37] The vaccine, trade name Oncept® (Merial Limited, Athens, GA,
USA), was produced and released from the manufacturer with permission from the
United States Department of Agriculture.
Trial Design and Vaccination Protocol

Horses were separated into two cohorts of five horses each; the first cohort
received a total dosage of 100 ug of human tyrosinase DNA vaccine while the second
cohort received 300 ug of human tyrosinase vaccine. The lower dosage was based on the
current dose recommendation used in dogs to treat melanoma and the higher dosage was
determined arbitrarily by multiplying the former dose by three. The vaccination protocol
consisted of four biweekly injections at days 0, 14, 28, and 42, and a booster vaccination
6 months after. Vaccine dosage and schedule were selected to be comparable with the
currently recommended protocol for its use in dogs to treat malignant melanoma.
[37,39,40,42] Horses were vaccinated in alternating pectoral muscles with 0.4 mL (100
ug) or 1.2 mL (300 ug) of vaccinate, using the VitaJet-3® (Bioject Inc, Portland, OR,
USA) needle-free injector device. The validation of this device as a proper delivery tool
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for DNA vaccinations in this species (as well as the identification of the pectoral muscles
as the ideal vaccination site), was previously described [43].
Sample Collection

Before each vaccination complete physical exams, tumor measurements and
blood collections were performed on all patients. Furthermore, in order to investigate
sustainability of tyrosinase-specific immune response blood samples were also collected
on specific re-checks at days 56, 86, 146 (corresponding to 2 weeks, 1 month and 3
months after the last vaccine) and 250 (2 weeks after booster). At each time point, 34 mL
of blood were drawn into sodium heparin tubes (30 mL) for peripheral blood
mononuclear cell (PBMC) isolation and into serum separator tubes (4 mL) for serum
separation. Furthermore, tumor biopsies were collected at days 00, 28 and 56
(corresponding to beginning/baseline, middle and end of the vaccination protocol) using
8 mm biopsy punch, local anesthesia and sedation when needed and immediately stored
in liquid nitrogen. A summary of the study plan can be seen in Table 6.2
Measurement of Humoral Immune Response

Serum was separated by centrifugation at 1,200 x g and stored at -20°C until use.
Standard enzyme-linked immunosorbent assays were used to determine both anti-HuTyr
and anti-EqTyr antibodies according to published methods [40,44]. In brief, Immulon®
(Thermo Fisher Scientific, Pittsburgh, PA, USA) microtiter plates were coated overnight
at 4°C with 50 µl/well (0.05 ug) of full-length recombinant HuTyr (Abnova Corporation,
Jhongli City, Taiwan, China) and then washed with phosphate-buffered saline

143

(PBS)/Tween (0.05%). A solution of 2% milk/PBS (150 µl/well) was then added to each
well with the objective of help avoiding unspecific binding, and after 1 hour incubation at
37°C plates were again washed. Patient serum (50 µl/well) was then added as serial
dilutions from 1:20-1:540, incubated for 1 hour at 37°C, and then washed. A secondary
horseradish peroxidase-conjugated goat anti-horse Immunoglobulin G (IgGT) antibody
(Bethyl Laboratories, Montgomery, TX, USA) was added (50 µl/well of a 1:500
dilution), incubated for 45 minutes, washed, and then developed using 100 µl a 3,3’,5,5”tetramethylbenzidine (TMB) substrate solution (Thermo Fisher Scientific, Pittsburgh,
PA, USA). Reactions were stopped after approximately 10 minutes by adding 50 µl/well
of 0.18 M H2SO4. The OD450 values were measured using the ELx800® (Bio-Tek
Instruments, Winooski, VT, USA) microplate reader instrument. Positive anti-serum
collected from fully vaccinated horse in a previous pre-clinical trial [44] was used as both
an inner-plate positive control and to normalize between plates for all equine samples.
The human GST protein (Abnova Corporation, Jhongli City, Taiwan, China) was used as
a negative control. Reactions were run in triplicate with average (OD450) results
reported, using negative controls as blanks.
Measurement of Cellular Immune Response

Isolation and Stimulation of PBMCs: Samples were diluted with equal volumes of
PBS, overlaid in Ficoll-Paque (GE Healthcare, Piscataway, NJ, USA), and separated by
density gradient centrifugation. The mononuclear layer was isolated and washed with
sterile PBS. Cells were resuspended in Roswell Park Memorial Institute (RPMI) cell
culture media (Cellgro, Mediatech, Manassas, VA, USA) containing 10% fetal bovine
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serum and antibiotics. Cells were then aliquoted (2 mL/well) into sterile cell culture
plates (Costar, Corning Life Science, Corning, NY, USA) and placed in a CO2 incubator
at 37°C. To determine cellular immune reactivity to tyrosinase, PBMCs were incubated
with synthetic peptides (NeoBioScience, Cambridge, MA, USA) encoding HuTyr. The
full-length of the HuTyr protein was used and divided into 35 individual 20 amino acid
long peptides, each overlapping the neighboring sequence by five residues, as previously
described. [41,44] The 35 individual peptides were separated in three pools (HT1, HT2
and HT3), each containing 11-12 peptides and overlapping each other by 20 amino acids,
as as previously described. [44] Aliquots (10 µg/mL) from each peptide pool were added
to separate 2mL wells in the cell culture plates containing PBMCs and incubated (37°C)
for 16 hours as previously described [41,44]. Positive controls were incubated with the
nonspecific mitogen concanavalin A (GE Healthcare, Piscataway, NJ, USA) (4mg/2 mL
well), whereas negative controls were incubated with a BLASTSM-queried random
peptide sequence [54], as previously reported. [41,44]
RNA Isolation: After incubation, cells were pelleted and washed with fresh PBS.
Total RNA was isolated using a commercial kit (RNeasy Mini Kit®, Qiagen,
Germantown, MD, USA) according to manufacturer’s specifications, which included a
sample homogenization step (QIAshredder®, Qiagen, Germantown, MD, USA) and
DNase treatment step designed to substantially reduce genomic DNA contamination
(RNase-Free DNase Set®, Qiagen, Germantown, MD, USA). The yield of total RNA
was determined by spectrophotometry (NanoDrop ND-1000®, Wilmington, DE, USA) at
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260 nm, whereas purity was estimated from the relative absorbance at 230, 260, and 280
nm (i.e., A260/A280 and A260/A230). Samples were stored at -80°C pending analysis.
Gene Expression Assays: Cell-mediated reactivity to HuTyr and EqTyr epitope
exposure was measured by determining IFN-γ mRNA production from stimulated cells.
Values were normalized to total CD4 mRNA expression to account for varying numbers
of these cells between samples, as previously described. [44,55,56] Previous work by our
laboratory documented a linear correlation between CD4 mRNA expression and absolute
number of CD4 cells [44]. RT-PCR was performed using TaqMan gene expression
assays® (Applied Biosystems, Foster City, CA, USA) designed by use of the
manufacturer’s online design software (TaqMan Custom Assay Design Tool®, Applied
Biosystems, Foster City, CA, USA). Target sequences included full-length equine IFN-γ
(NM_001081949) and CD4 (XM_001497051.2) mRNA. Probes were centered at exon 34 and 6-7 boundaries, respectively (Table 6.3).
Quantitative Real-Time PCR: RNA was reverse transcribed to cDNA using a
commercial kit (High Capacity cDNA Reverse Transcription kit®, Applied Biosystems,
Foster, CA, USA) and then pre-amplified (TaqMan PreAmp Master Mix kit®, Applied
Biosystems, Foster, CA, USA) according to the manufacturer’s specifications. Real Time
PCR reactions (10 µL) were conducted on ViiA™ 7 Real-Time PCR detection system
with a 384-well block module (Applied Biosystems, Foster, CA, USA) and in brief
included: 4.5 µl of diluted pre-amplified cDNA, 5 µl of TaqMan Gene Expression Master
Mix, and 0.5 µl of the appropriate TaqMan® gene expression assay (Applied Biosystems,
Foster, CA, USA); all which were loaded into qPCR plates using an automated pipetting
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system (epMotion 5070®, Eppendorf, Hauppauge, NY). Gene expression was measured
by the absolute quantification method. Standard curves for absolute quantification
analysis were created using 1:10 serial dilutions of known amounts of IFN-γ and CD4
Ultramer® DNA oligos (Integrated DNA Technologies, Coralville, IA, US) as templates.
Cycling parameters were set at 50°C for 2 minutes, 95°C for 10 minutes, followed by 40
cycles at 95°C for 15 seconds and 60°C for 1 minute. Baseline and threshold detection
levels were automatically assigned by the Real-Time PCR detection system’s software,
and then visually verified. Data analysis of absolute quantification experiments was
performed using the ViiA™ 7 Software v1.2.2 (Applied Biosystems, Foster, CA, USA);
while the amplification efficiencies for individual reactions were calculated using the
LinRegPCR Software v7.5 [57], as previously reported. [58-60] Assay efficiency (90%105%) and linearity (r2 = 0.980) were also confirmed before analysis. Replicates for each
sample (Ct values) were averaged and plotted on their corresponding standard curve to
obtain a copy number. Final reaction products were run on 2.0% agarose gels and
visualized with ethidium bromide for size verification.
Stimulation Index: For each sample, absolute IFN-γ mRNA copy number was
normalized to absolute CD4 mRNA copy numbers; results were reported in the form of a
stimulation index (SI), as previously described. [44,59,60] The measure of SI for HuTyr
(or TyrSI) was calculated as the ratio of IFN-γ copy number when PBMCs were incubated
with each of the three separate pools of HuTyr peptides (XHT) including the known
immunodominant region of the protein in humans [53], divided by IFN-γ copy number
when PBMCs were incubated the random peptides (YRP). In brief, TyrSI = XHT/YRP.
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Measurement of intra-tumoral immune response

Tissue collection and cryosection: Tumor biopsies were collected before (day 00),
during (day 28) and after (day 56) treatment. These 8mm biopsies were collected from
the tumor/normal tissue boundary and immediately frozen in liquid nitrogen and stored at
-80C. Frozen specimens were embedded with OCT compound (Tissue-Tek® O.C.T.
Compound, Sakura® Finetek) into cryomolds and then sectioned to 20-25µm thick
cryostat sections using a microtome-cryostat and finally mounted in Superfrost plus
slides (Thermo Fisher Scientific, Pittsburgh, PA) and stored in -80C until staining.
Single and double immunofluorescence staining: For immunostaining of tumor
infiltrating lymphocytes (TILs), single immunofluorescence of CD8 was performed for
the identification of cytotoxic T cells, while dual immunofluorescence of FoxP3
(intracellular) and CD4 (cell surface) was performed for the identification of regulatory T
cells. For this purpose cryostat sections were first gently washed with phosphate-buffered
saline (PBS) and then fixated for 15 min with a 4% Paraformaldehyde (PFA) solution, all
at room temperature. Sections were washed again with PBS and blocked with 100 µl of
10% fetal bovine serum for 1 hour at room temperature. Sections were washed and
incubated for 1 hour with 1ug/sample of the primary antibodies diluted in PBS. These
included the Mouse anti-Horse IgG1 antibodies against the equine CD8 (HT14A) and
CD4 (HB61A) lymphocyte surface markers (WSU Veterinary Monoclonal Antibody
Center, Pullman, WA, USA) and the Rat anti-Mouse IgG antibody, reported to cross
react with equine tissue [61,62], against the intracellular marker Foxp3 (FJK-16s) for
specific staining of regulatory T lymphocytes (eBioscience, Inc., San Diego, CA, USA).
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Sections that were going to be stained for the Foxp3 intracellular marker where subjected
also to a permeabilization step using 100 µl of a 0.1% Triton X solution for 30 min at
room temperature. For isotypic controls 1ug/sample of the conjugated antibodies Goat
anti-Mouse IgG2a-k + Alexa 647 and the Goat anti-Rat IgG + Texas Red (Beckman
Coulter, Inc., USA). Tissue sections were then washed and incubated for 45 min at room
temperature and protected from the light with 1ug/sample of the fluorescence tagged
secondary antibodies. These included a Goat anti-Mouse Alexa Fluor® 647 for sections
stained for CD8, a Goat anti-Rat Alexa Fluor® 647 for Foxp3 sections and Goat antiMouse Alexa Fluor® 488 for sections stained for CD4 (Jackson ImmunoResearch Labs,
Inc., West Grove, PA, USA). Sections were then washed one last time with PBS and
cover slipped using the antifade reagent Prolong® Gold (Life Technologies Corporation,
Grand Island, NY, USA), and finally incubated at room temperature to cure overnight.
Confocal microscopy and quantification of tumor infiltrative lymphocytes:
Immunostained sections were then examined using a Leica TCS SP2 laser scanning
confocal microscope (Leica Microsystems, Inc., Buffalo Grove, IL, USA) at the Bio
Imaging Facility at the University of Tennessee for simultaneous multicolor fluorescent
imaging. Double fluorescence for green and red channels was imaged using the excitation
of argone and diode laser at the wavelengths of 488 nm and 633 nm, respectively.
Multichannel images were recorded by sequential excitation to avoid cross-talk. Tumor
biopsy samples were scanned to ascertain the areas with the higher density of
immunopositive TILs on each tissue, from these at least 5 high power fields using an
immersion-oil Plan-Apochromat 40x objective (higher magnification was selected to

149

allow for proper co-localization of dual markers in Tregs) where randomly selected, as
previously reported [50,51,63]. For each selected field 3D Z series with a 4µm step size
was obtained, these consisted each of 6 Z slices for each immune marker. Further
identification and quantification of immunopositive TILs was performed on the collected
digitalized maximum intensity projections images by using the NIS-Elements v3.0
software (Nikon Instruments, Inc., Melville, NY, USA). Positive cells for CD8 and CD4,
and double positive cells for CD4/Foxp3 were identified and counted by two independent
observers (Biggerstaff, Prater), with vast experience in the field, but without knowledge
of any clinical information. The mean of immunopositive cells in at least five fields was
selected for each analysis and lastly expressed as a ratio of cytotoxic T cells to regulatory
T cells (CD8+ : Foxp3+/CD4+), as previously reported [46,47,50,51,64-69].
Evaluation of vaccine safety and toxicity

In order to assess for any signs of local toxicity the owners of the vaccinated
animal were instructed to monitor and report to the investigators any vaccine site reaction
in the form of noticeable localized inflammation and pendulous edema or any overall
abnormal behavior in the vaccinated animal through the next 24 to 48 hours following the
vaccination events. Furthermore, with the purpose of providing a more complete vaccine
safety profile and to assess for signs of any possible systemic toxicity blood samples were
collected at baseline at day 00 and at the end of the core vaccination protocol at day 56
and submitted for analysis at the UTCVM’s Clinical Pathology laboratory, including a
complete blood count (CBC) and a serum chemistry panel (creatinine, BUN, AST, GGT,
total bilirubin, CK, albumin, globulin, and glucose). The obtained pre- and post-treatment
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values were compared in order to assess for the appearance or worsening of one or more
abnormal laboratory values at the end of the core vaccination protocol. Toxicities were
graded according to the Veterinary Cooperative Oncology Group’s common terminology
for adverse events (VCOG-CTCAE). [70] If any grade III or IV toxicities were noted
during the study period, any horse experiencing them would immediately exit the study.
Evaluation of clinical response

Although the main objective of the study was to assess safety and to document
vaccine-specific immune responses, anti-tumor clinical efficacy was also recorded in the
form of changes in tumor size following vaccination. Consecutive tumor measurements
were performed as following: From all tumors present in one single patient target and
non-target lesions were selected at the day of enrollment. Target lesions were selected
based on larger size (with tumors smaller than 10mm being excluded from consideration
as target lesions, but potentially remaining as non-target lesions), ease of reliable
repetitive measurements and on being representative of organs involved. Only superficial
skin lesions or palpable lymph nodes able to be clinically measured with standard
calipers were selected. When more than five melanomas were present in one single
patient a maximum of 5 lesions total and a maximum of 2 lesions per location (i.e. ventral
surface of the tail, forehead, perianal area) were selected as target lesions, as describe by
the RECIST criteria. [71,72] All other melanomas present were identified as non-target
lesions. These lesions were regularly assessed throughout the vaccination protocol for
changes in both size and appearance (e.g., signs of depigmentation or necrosis). Clinical
measurements were performed using standard calipers, reported as percentage changes in
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the tumor’s largest diameter (except in the case of metastatic lymph nodes, where the
smaller diameter was reported) and documented when possible with color photography,
as previously described by the RECIST guidelines for clinical measurements. [71-75]
Objective anti-tumor responses for all individual lesions (target and non-target) in each
patient were estimated by the comparison of pre and post-treatment measurements and
reported using a modified RECIST criteria. The complete response (CR) of a single
lesion was defined as its total disappearance. Partial response (PR) was defined as a
minimum of 30% decrease in the longest diameter of the lesion. Progressive disease (PD)
was defined as a minimal increase of 20% in the longest diameter of the lesion. Stable
disease (SD) included lesions with neither sufficient shrinkage to qualify as a partial
response nor sufficient increase to qualify for progressive disease. [71,72] In order to
assess patients’ overall response or progression of disease, tumor burden was also
estimated at baseline. This was calculated by adding the longest diameters of all target
lesions in a patient at day 00 before treatment and reported as the baseline sum of longest
diameters (SLD), as previously described [71,73,74,75]. This measure was used as a
reference against which to compare subsequent responses throughout the study, including
responses at the end of the core vaccination protocol at day 56 and at the end of the study.
Statistical Analysis

All statistical comparisons between pre-vaccination and post-vaccination
immunoreactivity values in the three different types of immunoassays described herein,
as well as the assessment of the potential effect of various population and
clinicopathological variables (e.g., vaccine dose, tumor grade, sex, age and baseline
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tumor burden) on them, were performed using a multivariate analysis of variance
(repeated measure MANOVA), to account for multiple comparisons of dependent
variables. [76] A significant difference was defined as P < 0.05. For cellular and humoral
immunoassays a positive immunological response threshold, above which values would
be considered positive for the induction of a significant antigen-specific immune
response, was set at three standard deviations above the group’s baseline mean value, as
previously described. [44, 56] All statistical analyses were performed using SAS
statistical software (version 9.4, SAS Institute Inc., Cary, NC).
Results
Evaluation of Humoral Immune Response

A gradually increasing trend in the antibody levels (IgG) of all but two horses
(EQ-01 and EQ-06) was noted through the HuTyr vaccination protocol’s core period (day
00 to day 56), as measured by a tyrosinase-specific indirect enzyme-linked
immunosorbent assay. A humoral positivity threshold, above which observed values
would be considered positive for the induction of a significant immune response, was set
three standard deviations above each cohort’s baseline mean value, at an OD450= 0.438
(x̄ = 0.35, σ = 0.03) for the first cohort and at an OD450= 0.370 (x̄ = 0.33, σ = 0.02) for
the second, as previously described [44,56] and shown in Figure 6.2A and B. Most horses
in both cohorts showed values above their respective cohort thresholds as early as by the
day of the second vaccine (day 28). By the time of the first immunogenicity recheck (day
56) after the end of the protocol’s core period all but two horses (again EQ-01 and EQ06) had reached and sustain antibody levels above these mentioned thresholds.
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Furthermore, most horses in the study continue to sustain increasing antibody levels by
the time of the second immunogenicity recheck at day 86. These increments in humoral
values from pre-vaccination to post-vaccination levels at the point of best overall immune
response (either at day 56 or 86), ranged from two to fourfold increments over baseline
and were statistically significant (p = 0.0037). Further analysis of the anamnestic period
evidenced a dramatic drop in immunoreactivity values below threshold by the time of the
3 month recheck (day 146), reaching their all-study lowest points by the day of the 6
month recheck at day 236 in all patients. Day 236 was also the day all patients received a
booster vaccination, two weeks after which (last immunogenicity recheck at day 250) all
patients’ (but EQ-06) antibody levels rebounded and experienced their highest levels
across the study. These increments ranged from an approximate two to fivefold elevation
over the baseline values, and were also statistically significant (p < 0.0001). No
significant difference in the degree of humoral response was observed among dosing
cohorts (p = 0.1032).
Evaluation of Cellular Immune Response

Similar to humoral assays, a positivity threshold was also set at three standard deviations
above each cohort’s baseline mean value, at a TyrSI = 5.5 (x̄ = 3.3, σ = 0.7) for the first
cohort and at a TyrSI = 2.7 (x̄ = 1.9, σ = 0.2) for the second, as previously described
[44,56] and shown in Figure 6.3A-B. As it is expected with this type of immunoassays,
the variability of responses between patients was high; however, the variability within a
specific patient was low. [44,56,] Furthermore, some general common tendencies could
be observed. All patients experienced a significant initial increase in immunoreactivity
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after the first vaccination; which allowed for the observation of positive cellular reactivity
above threshold as early as by day 14 in all horses form the first cohort and in most from
the second. The remaining two horses rose above threshold by the time of the next
vaccine at day 28 (EQ-09) or considerably later by the time of the second
immunogenicity recheck by day 86 (EQ-10), the latter even showed by then an almost
fourfold increase over baseline. Following the end of the protocol’s core vaccination
period most horses reached their peak in immunoreactivity at the first recheck at day 56,
but some did so at the second immunogenicity recheck at day 86. These increments in
immunoreactivity from pre-vaccination to post-vaccination at the point of best overall
immune response (either at day 56 or 86), ranged from two to fourfold increments over
baseline, and were statistically significant (p = 0.0004). Further analysis of anamnestic
response showed a general drop in immunoreactivity values below threshold in most
cases at the three and six month rechecks, just as if was seen with humoral assays. When
vaccination was reinstituted (boosters), immunoreactivity values tend to observed a
dramatic increase, which in the case of four horses in the first cohort and three in the
second was enough to bounce their immunoreactivity values back above threshold levels
(and in the case of one of them to finally set it above threshold for the first time). These
increments represented values as high as six, fifteen and even a more than eighty fold
increases over baseline. On the hand, the remaining three horses (EQ-01 from the first
cohort and EQ-06 and 08 from the second) failed to show this increasing behavior, as
measured at two weeks after re-vaccination. When compared to one another the two
dosing cohorts did not show a significant difference in regarding their degree of cellular
immune response (p = 0.4878).
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Quantification of TIL and Evaluation of Local Immune Response

When intratumoral CD4+Foxp3+ regulatory T cells from biopsied specimens
were subjected to double immunofluorescence staining with anti-CD4 and anti-Foxp3
antibodies, the former showed a cell membrane expression pattern while latter showed
intracellular expression. In the case of intratumoral cytotoxic CD8+ cells the immune
marker CD8 showed a membrane expression pattern, as it can be seen in Figure 6.4A–D).
Although CD8+ and CD4+/Foxp3+ T cells were both identified in all tumor biopsies at
all three key time-points (day 0/before treatment, day 28/during treatment and day
56/after treatment), clear changes in trends of individual TIL numbers and proportions
could be observed during vaccine treatment. In the case of effector CD8+ cytotoxic T
cells their intratumoral numbers experienced an increasing trend during treatment, as it
can be observed in Figure 6.4E; This increment in the mean absolute number of
intratumoral CD8+ cells from 14.4 cells/HPF (range 9.2-23.8 cells/HPF) at baseline to
24.5 cells/HPF (range 15.3-44.3 cells/HPF) by day 28 and to 49.3 cells/HPF (range 22.167.5 cells/HPF) by the end of treatment at day 56 was statistically significant (p <
0.0001). These CD8+ increases ranged from barely a twofold increase in EQ-01 to
fivefold increases in EQ-03, 07 and 10 and even a sevenfold increase in EQ-02 during
vaccination treatment. No significant difference was found between dosing cohorts in
respect to these changes (p = 0.1621). On the other hand the intratumoral numbers of
immunosuppressive CD4+/Foxp3+ regulatory T cells appeared to have experienced a
decreasing trend during treatment, as it seen in Figure 6.4F. This decrease in the mean
absolute number of intratumoral Tregs from 14.1 cells/HPF (range 1.7-36.0 cells/HPF) at
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baseline to 10.4 cells/HPF (range 1.3-29.3 cells/HPF) by day 28 and finally to 7.5
cells/HPF (range 0.3-20.0 cells/HPF) by the end of treatment at day 56 was also
statistically significant (p = 0.0019). These decreases in Treg numbers ranged from a
twofold decrease in EQ-01, 02, 04, 05, 06 and 08 to fivefold decreases in EQ-07 and 10
and even a sixfold decrease in EQ-03 during vaccination treatment. Finally, the ratio
between these two individual TIL populations was also calculated for each tumor tissues
during vaccination treatment. This ratio presented an increasing trend during treatment,
as it can be observed in Figure 6.4G. Characterized by an increment in the ratio’s mean
from 1.87 (range 0.31-6.20) at baseline to 4.49 (range 0.62-12.07) by day 28 and finally
to 22.7 (range 1.10-138.35) by the end of treatment at day 56. These increments ranged
from a fourfold increase in EQ-05, fivefold increases in EQ-01 and 06 to even a eleven, a
fifteen, a eighteen and a higher than twenty fold increase in EQ-02, 10, 07 and 03,
respectively. Nonetheless these were not statistically significant (p = 0.1461). And Just as
with its individual components, no significant difference was either found between
dosing cohorts in respect to changes in this TIL ratio (p = 0.4806)
Safety and Toxicity

No significant adverse events were observed. As described, from all these
vaccination events, which total to 50 (with half of them entailing three injections per
horse per event), only two episodes of vaccine site reactions were observed. These
consisted of short incidents of mild pendulous edema localized to the injection site, which
completely resolved without any treatment by the second day. These occurred in two
separate patients, both from the low dose cohort and both after the third vaccine. Despite
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these isolated events, the two horses remained in the study and received two more
vaccinations without experiencing any recurrence of these adverse reactions. No
important systemic toxicity as assessed by physical examination, hematopathology, and
serum chemistry was noted throughout the trial, as demonstrated in Tables 6.4 and 6.5.
Only one grade 2 elevation of creatine kinase levels (in EQ-07) and two grade 1
elevations in serum total bilirubin (EQ-06 and EQ-09) were observed after completion of
the four vaccinations. [70] Furthermore, two patients (EQ-01 and EQ-06) presented with
abnormally elevated globulin levels before vaccination; these decreased (but without
reaching normal levels) by the end of the vaccination protocol. None of these laboratory
abnormalities were associated with noticeable clinical signs in these patients.
Preliminary Evaluation of Clinical Response

As previously stated the main goal of the present study was to evaluate safety and
to document data on immune response, nonetheless clinical response in the form of
reductions in tumor size was also evaluated as a secondary objective. A gradually
decreasing trend in patients’ tumor burden was noted in all but one patient (EQ-01)
during the vaccination protocol’s core period (day 00 to day 56); with patients reaching
their best overall clinical response by day 56 (Figure 6.5A and B). [71,72] By this point
in the study seven (four from the low dose cohort and 3 from the high dose cohort)
patients had achieved enough tumor reduction to qualify as partial responses, with the
rest sustaining stable disease, according to modified RECIST criteria for veterinary
patients. [71,72] Furthermore, while this decrease in the baseline sum of longest
diameters by day 56 was found to be statistically significant (p < 0.0001). Similarly,
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measurements obtained in the end of the anamnestic period (which included one extra
booster vaccination) at day 250 were found to remain significantly different from the
baseline sum of longest diameters collected at day 00 (p < 0.0001). No significant
difference was found between both dose cohorts in respect to reductions in tumor size (p
= 0.7188). By the end of the anamnestic period no complete responses were observed, but
all the horses that had achieved partial response (PR) were able to sustain it. From the
patients that showed only stable disease by day 56, one was able to able to achieve PR at
the last recheck at day 250 (two weeks after the booster vaccination). The other two
although experience some small degree of tumor burden reductions, these were gradually
lost and by the end of the anamnestic period and their tumors had almost returned to their
normal sizes. Nonetheless no patients experienced progressive disease under therapy. All
horses where alive at the end of the study, which is expected given the slow progressive
nature that characterizes this disease in horses, but by the time of preparation of this
manuscript two patients had already been euthanized. This occurred shortly after the
completion of the study due to disease progression (EQ-01) as well as to reasons not
related to disease or treatment (EQ-04).
Discussion

Herein, we described the first pre-clinical dose escalation trial evaluating the use
of a tumor antigen-specific immunotherapy to treat a malignancy in equine tumor-bearing
patients. For this purpose we enrolled two cohorts of melanoma-bearing horses and
assigned them scalating doses of a human tyrosinase DNA plasmid vaccine. Patients then
went through a vaccination protocol that included four biweekly vaccinations (core
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protocol) and one 6-month booster vaccine. Both blood and tumor tissue samples were
collected from each patient at set time-points during the protocol. These samples were
used to adequately evaluate the presence, progress, magnitude, timing and anamnestic
persistence of both humoral and cell mediated immune response to vaccination by the use
of specially designed immunoassays optimized to measure immunoreactivty specific to
the vaccine’s tumor-antigen target (tyrosinase).
This plasmid was designed to be uptaken by muscle cells and then transcribed
[36]. The processed protein would be expected to generate a self-tolerant tyrosinasespecific immune response. Similar to previous reports evaluating this xenogeneic
vaccine, the immunoreactivity measured was to the HuTyr protein and not to the
orthologous equine protein [18,25,27]. Conceptually, the purpose of xenogeneic
vaccination is to induce cross-reactive immune responses in tumor-bearing horses and/or
overcome

auto-regulatory

mechanisms

that

have

allowed

tumors

to

escape

immunosurveillance [37]. However, reactivity to the xenogeneic protein is routinely
measured as an immunologic endpoint, and initial evidence suggests a correlation
between these values and clinical outcome [25,27]. In this study clinical response, in the
form tumor burden reductions, was also evaluated as secondary objective.
HuTyr vaccination appeared to successfully elicit both humoral and cell-mediated
reactivity to the HuTyr protein in both cohorts. Based on defined threshold values, all
horses but one horse per cohort, EQ-01 and 06, exhibited statistically significant positive
humoral responses to vaccination at the end of the vaccination core period (p = 0.0037).
And although antibody levels fell below threshold by the time of the three and six month
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post-vaccination rechecks the administration of a single booster vaccine quickly and
dramatically reversed this trend, with most horses reaching their all-time highest
immunoreactivity levels in the study (ranging from two to fivefold increases over
baseline values). This rapid renewal in the production of tyrosinase-specific antibodies
after the booster was expected, and mimics what we observed in the population of
healthy horses vaccinated in our previous pre-clinical study. [44] Interstingly, EQ-01 and
06 were also the patients that responded the poorest to the booster stimuli and were
barely capable of crossing the positivity threshold. These two patients represented the
only two melanoma grade IV cases in the study, and so comprised the patients with the
heaviest starting tumor burden. Overall, these results are consistent with an appropriate
immune response to the (expected) transient expression of a plasmid vector. When
evaluating cellular

immune

response

a

similar

trend

of

overall

increasing

immunoreactivity levels could be observed. That being said, significant variability was
observed through all individual reponses. Wide variability in the immune response is an
expected finding in studies of this nature due to both small sample size and the
heterogeneity of outbred populations. [56,57] Sample size is typically limited by the cost
not only of the immunotherapeutic but also of the assays used to monitor the immune
response (especially cellular immune response), which is particularly true when dealing
with large animal patients, such as horses. This heterogeneous populations, however,
represented a good sampling of the different presentations and grades of equine
melanomas that are out there in the field, ranging from barely noticeable tumors (like in
the case of EQ-10) to large necrotic and ulcerating confluent melanomas (like the cases
of EQ-01 and EQ-06). Overall, the equine tumor-bearing population here vaccinated
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exhibited statistically significant positive cellular responses to vaccination at the end of
the core period (p = 0.0004). The effect of the booster vaccine was similar to the one
observed with humoral response, and brought the immunoreactivity values of most horses
again over the positivity threshold (after these has dropped during the anamnestic period);
except once again for EQ-01 and 06. Furthermore, vaccination immunotherapy was able
to alter the lymphocyte dynamics inside the tumor itself in most patients, promoting both
the recruitment of more cytotoxic T cells into the malignancy and reducing the
proportions of regulatory immunosupresive T cells in the tumor, both in a statistically
significant manner.
As mentioned before, the assessment of the degree of clinical response the
patients may experience while on therapy was not a main objective of this study.
Nevertheless, clearly decreasing trends in tumor burden where observed in almost all
horses, with several being able to achieve partial responses (RECIST criteria) [71,72],
that were sustained until the end of the study. Once again EQ-01 and EQ-06 (the horses
with the higher initial tumor burden) were unable to move away from the stable disease
category and were observed as the lowest responders of their cohorts in regard to clinical
response too. Important to mention, that although no objective positive response was
measured in EQ-01, a subjective and noticeable increase in appetite and weight was
gradually seen in this horse through therapy. Similarly EQ-03, 07 and 10 experienced the
higher percentage reductions in tumor burden qualifying as the higher responders in their
cohorts. This mimics what was seen in the immunoassays, which hints of a correlation
between immunoreactivity values and clinical outcome. Figure 6.6 shows an example of
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a melanocytic tumor in one of the study patients that had decreased in size during
vaccination (tumor measurement at baseline and at the end of the vaccination core
protocol are placed side to side for comparison).
As demonstrated in Table 6.4, no significant adverse events were observed
through the duration of the study. Two patients experienced grade 1 toxicity associated to
a mild rise over normal levels in total bilirubin values (with other liver function values
within normal limits), patients were otherwise healthy and never manifested any signs of
dysfunction. One patient experienced grade 2 toxicity associated with elevated levels of
creatine kinsase at the end of the vaccination protocol. This patient belonged to the high
dose cohort, and received three separate intramuscular shots at every vaccination event, if
this was associated with the elevations observed in this marker of muscle injury was not
determined and none of the other horses in the triple dose cohort experienced similar
events. Finally two patients (EQ-01 and EQ-06) started the study with already elevated
globulin levels, most likely associated to higher tumor burden (these were the only
melanoma grade 5 subjects included in the study); interestingly enough this globulin
levels where measured as closer to normal by the end of vaccination. No other laboratory
abnormalities were observed. With respect to reactions at the vaccine site, only two (out
of 100 vaccination events) were reported. These were mild episodes of edema at the site
and resolved without treatment. Overall, the vaccine appears to be safe and well tolerated
at the doses herein described.
Also regarding dosing, this appeared to have no effect in either immune or clinical
response, as it is commonly observed with DNA based anti-cancer vaccines. Being that
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the lower dose seems just as effective as the higher dose in generating similar degrees of
immune and clinical response, and taking in account other factors such as drug cost, the
minimum effective dose (100ug of tyrosinase plasmid DNA) should be recommended.
This dose corresponds to the same one being used in dogs to treat melanomas. [77]
The information produced in this project will be useful to the owners of horses at
risk or diagnosed with melanomas. Demonstration of immunoreactivity of this vaccine
will also be useful to veterinarians who are treating horses with melanomas by providing
additional therapeutic options for their patients. Among the important details yet to be
elucidated are the adequate timing of boosters, the identification of predictor factors that
could early recognize which horses are going to respond well to this therapy and which
ones are not (so far, subjectively advance age and initial higher tumor burden/grade
appear to be inversely proportional to response, as expected) and the elucidation of
strategies to improve response to this vaccine (e.g., xenogeneic prime/syngeneic booster
strategy, co-expression of more than one protein target in the same plasmid,
experimentation with other vectors, such as viral ones).
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Appendix of Tables and Figures
Table 6.1. Description of important characteristics of the study population. a Modified grading system for equine melanomas (Curik, et al. 2013). b Dermal
melanomas: melanomas located within deep dermal locations . Dermal melanomatosis: multiple, disseminated and confluent dermal melanomas. c Low
dose vaccinations were performed using 100ug of human tyrosinase, while high doses used 300ug. d Intratumoral chemotherapy with platinum compounds
(either carboplatin or cisplatin).

Study

Breed

ID

Age

Gender

(years)

Reproductive

Tumor

Tumor

Dosing

Previous

staus

gradea

clasificationb

cohortc

therapies

EQ-01

American Paso Fino

24

Male

intact

V

dermal melanomatosis

Low

chemotherapyd + hyperthermia

EQ-02

Andalucian

16

Male

neutered

IV

dermal melanomatosis

Low

chemotherapyd

EQ-03

Arabian

14

Female

intact

II

dermal melanomas

Low

surgery

EQ-04

Arabian

21

Male

neutered

II

dermal melanomas

Low

cimetidine

EQ-05

Irish Draught Horse

18

Male

neutered

III

dermal melanomas

Low

none

EQ-06

Irish Draught Horse

16

Male

neutered

V

dermal melanomatosis

High

cimetidine, surgery + cryotherapy

EQ-07

Arabian

14

Female

intact

II

dermal melanomas

High

surgery

EQ-08

American Paso Fino

13

Male

neutered

IV

dermal melanomatosis

High

chemotherapyd

EQ-09

American Quarter horse

12

Female

intact

IV

dermal melanomatosis

High

none

EQ-10

Oldenburg

11

Female

intact

I

dermal melanomas

High

none
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Table 6.2. Study schedule.

Vaccine core protocol

Immunogenicity rechecks

Booster

Vac #1

Vac #2

Vac #3

Vac #4

Recheck

Recheck

Recheck

Vac #5

Recheck

Day 00

Day 14

Day 28

Day 42

Day 56

1 month

3 months

6 months

Day 236

HuTyr vaccination

X

X

X

X

Physical examination

X

X

X

X

X

X

X

X

X

Tumor measurements

X

X

X

X

X

X

X

X

X

Blood collection

X

X

X

X

X

X

X

X

X

Biopsy collection

X

CBC/chemistry

X

X

X

X
X

CBC: complete blood count

Table 6.3. Equine TaqMan® primers and probes used for RT-PCR measurement of gene expression of both target and normalizer genes. F for forward
primer, R for reverse primer and P for probe. FAM: 6-carboxy-fluorescein, probe fluorophore. TAMRA: tetramethylrhodamine, probe quencher.

Gene name

Primers and probes

Interferon gamma

E-IFNγ-F

5’-AGCAGCACCAGCAAGCT-3’

E-IFNγ-R

5’-CTTTGCGCTGGACCTTCAG-3’

E-IFNγ-P

5’-(FAM)CAGATTCCGGTAAATGAT(TAMRA)-3’

E-CD4-F

5’-ACCAGAAGACACTGGTGTTCAACATAA-3’

E-CD4-R

5’-AGTCTCTCGCACAGTCTATGCGAAAGAGGG-3’

E-CD4-P

5’-(FAM)ACATCTTGGTGCTTTCCAGAA(TAMRA)-3’

CD4

Sequence

Amp. length
76bp

82bp
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Table 6.4. Hematological evaluation: comparisson between complete blood cell counts and serum
chemistry values at the beginning (day 00) and end of vaccination (day 56). WBC: white blood cell count;
RBC: red blood cell count, AST: aspartate aminotransferase; GGT: gamma-glutamyl transpeptidase; BUN:
blood urea nitrogen; CK: creatine kinase.
Table 3
Toxicity and adverse events in the study

Adverse event

Grade 1
No. of
%
Patients

Grade 2
No. of
%
Patients

Systemic adverse events:
Biochemistry panel abnormalities
Aspartate aminotransferase
Gamma-glutamyl transpeptidase
Total billirubin
Blood urea nitrogen
Creatinine
Creatine kinase
Glucose
Albumin
Globulin, increase

3

20

1

7

CBC abnormalities
White blood cell count
Red blood cell count
Platelet count
Hematocrit
Hemoglobin
Local adverse events (75 vaccinations):
Injection site reactions

2

13

CBC: Complete Blood Cell count
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Figure 6.1. Tumor distribution in the study population.
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A

B

Figure 6.2. Humoral immune response trends through time in horses treated with HuTyr vaccine. (A) IgG
humoral response trends at 1:20 dilutions for horses in the Low Dose cohort. The positivity threshold, above
which values are consider positive for the induction of a significant specific immune response was set at an
OD450= 0.438, and is denoted by a dashed line. (B) IgG humoral response trends at 1:20 dilutions for
horses in the High Dose cohort. The positivity threshold was set at an OD450= 0.450. Arrows represent
actual vaccination days.
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Figure 6.3. Cellular immune response trends through time in horses treated with HuTyr vaccine. (A) TyrSI
cellular respond trends for horses in the Low Dose cohort. The positivity threshold, above which values are
consider positive for the induction of a significant specific immune response was set at a TyrSI = 5.5, and
is denoted by a dashed line. (B) TyrSI cellular response trends for horses in the High Dose cohort. The
positivity threshold was set at a TyrSI = 2.7. Arrows represent actual vaccination days.
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Figure 6.4. (A-D) Characterization of equine tumor infiltrating lymphocytes by single a double staining
immunofluorescence and confocal microscopy. (A) Left and middle, results of simple immunofluorescence
acquisition with each individual antibody (CD4+ green cell surface staining pattern, Foxp3+ red
intracellular pattern); right, double immunofluorescence acquisition with yellow staining representing
antibody co-localization (B) Immunofluorescence staining using the equine CD4+ antibody (red) showing
characteristic cell surface staining pattern.(C) High magnification of typical CD8+ Cytotoxic T cells (630x)
(D) High magnification of typical CD4+/Foxp3+ regulatory T cells (630x). (E-G) Box plots showing
changes during HuTyr vaccination treatment in the population numbers of intratumoral CD8+ cytotoxic
and CD4+/FOXP3+ regulatory T cells, as well as in the ratio between this two TIL populations. The box
shows the 25th to 75th percentile, the horizontal line represents the median; the whiskers extend to the 10th
and 90th percentiles, and the individual circles represent outliers.
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Figure 6.5. Changes in melanoma tumor burden during HuTyr vaccine treatment, expressed as percentage
changes in the sum of the longest diameters of target lesions for Low Dose (A) and High Dose (B) cohorts.
Higher horizontal dotted line, set at 20% increase over baseline tumor measurements, represents the limit
between stable disease (SD) and progressive disease (SD); while dotted line set at -30% decrease below
baseline represents the limit between SD and partial response (PR), according to a modified RECIST
criteria. Arrows indicate actual vaccination points.
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Figure 6.6. Example of clinical response during treatment. Dermal melanoma being treated with the
Oncept melanoma vaccine (Merial, Ltd, Athens, GA). (A) Tumor before treatment. (B) Results after
treatment with four doses of vaccine, note reduction in tumor size and volume (tumor appears significantly
flatter also).
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Chapter 7 : Final Discussion and Conclusions
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Final Discussion and Conclusions

Tyrosinase, a glycoprotein essential for melanin synthesis, and the target antigen
used in the anti-cancer vaccine evaluated herein, is significantly overexpressed in equine
melanoma tissue in comparison to normal equine skin tissue; this provides “proof of
target” for the use of anti-melanoma vaccines targeting this antigen in this species
The VitaJet-3 needle free injector was identified as the optimal device for
delivering a plasmid DNA vector such as the pING/tyrosinase into the muscle tissue of
horses. The pectoral muscles were identified as the optimal (for the horse and the
operator) vaccination site using the VitaJet-3 needle free injector in the horse. Clipping
the hair at the vaccination site prior to vaccination does not appear to be necessary for
adequate vaccine deposition; however it does improve visualization of the site and it is
highly recommended (especially in horses with thicker coats).
This plasmid based xenogeneic DNA vaccine was able to induce significant
tyrsosinase specific immune responses (both cellular and humoral) in healthy horses, as
well as tumor-bearing equine patients. Increases in dose, however, do not appear to have
a significant impact on response, either immunological or clinical (at least as far as with
the dosages used in this study); this correlates with what has been reported for similar
human studies using DNA vaccines to treat cancer. Although evaluating clinical response
was not the primary objective of this study, vaccine administration was associated with
measurable tumor burden reductions in treated patients.

179

This xenogeneic DNA vaccine appears to be safe and well tolerated in horses,
based on over 150 vaccinations performed in these preclinical studies, and the very low
incidence of observed adverse events and the absence of signs of systemic of toxicity.
Future steps should include the implementation of larger studies with this
immunotherapeutic (small sample size constituted an important limitation of the studies
presented herein), as well as to continue the follow up of the patients already enrolled in
this study. Most importantly, future projects should include the search for new strategies
to improve the effectiveness of this vaccine (both in intensity and duration of response).
Among these strategies, some that merit further investigation are “prime/boosting”
vaccination (using xenogeneic followed by syngeneic vaccination), the evaluation of new
delivery vectors (e.g., viral vectors), and the co-expression of more than one transgene
immune target into an existent plasmid vector (e.g., more than TAA per vector and/or the
inclusion of adjuvant transgene sequences, such as of GM-CSF or IL-2 or IL-12).
Finally, the information produced in this project will be useful to the owners of
horses at risk or diagnosed with melanomas. Demonstration of immunoreactivity of this
vaccine will also be useful to veterinarians who are treating horses with melanomas by
providing additional therapeutic options for their patients. At the same time the general
approach and methodology taken in this study could be applied to the design and
evaluation of new tumor-antigen based immunotherapeutics for the treatment of different
cancers, not only in the horse but in other veterinary species as well.
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